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“Medicine is a science of uncertainty and an art of probability.” 
- Sir William Osler (1849 – 1919)
SHORT POPULAR SCIENCE SUMMARY  
This thesis aimed to investigate different long-term effects of menopausal hormone therapy (MHT) 
and oral antibiotic treatment – both common pharmacological treatments, which either include 
oestrogens or may alter the metabolism of oestrogens. Three of the included publications were 
based on extensive nationwide and population-based cohort studies evaluating the risk of cancer 
among MHT users, including virtually all Swedish women exposed to MHT. Menopausal 
hormone therapy is the primary treatment for vasomotor symptoms of menopause, which are 
experienced by 50 – 80% of women worldwide. One of the publications focused on oral antibiotic 
treatment exploring the posed association with colorectal cancer risk since the widespread use of 
common antibiotics and the increasing burden of cancer highlights the need to investigate all 
potential risk factors.  
We have shown that the cancer risk associated with systemic MHT is seemingly overestimated, 
given the net effect of menopausal hormones on the cancer risk was only slight. The excess cancer 
risk was mainly linked with an increased risk of breast and other central female reproductive organ 
cancers, particularly among women who initiated treatment at an older age. In contrast, we found 
a lower risk of gastrointestinal tract cancers among MHT users, and our data indicate that 
prediagnostic use of unopposed oestrogens-only may even improve survival from colorectal 
cancer. These findings could further support the chemopreventive role of oestrogens associated 
with sex hormone-related cancers.  
Whereas we have seen that the number of MHT prescriptions has remained rather stable during 
the past decade, the number of MHT prescriptions dropped by over 30% in Sweden after the 
millennium following trial results indicating higher breast cancer risk. This drop in the MHT 
prescriptions can partly be explained by fear of the MHT use associated carcinogenic effects. 
However, our results have shown that menopausal hormones do not appear to increase the cancer 
risk when initiated near to menopausal onset among otherwise healthy women without 
contraindications or an increased risk of breast, ovarian or endometrial cancer. 
Furthermore, we found an association between exposure to commonly prescribed antibiotics and 
excess colorectal cancer risk, linked with especially broad-spectrum antibiotics. However, 
evidence for the dose-response relationship was weak, and the shown association may not be 








Despite advances in cancer treatment and surgery, cancer-related mortality remains the leading 
cause of death globally, harvesting over ten million lives annually. While the risk factors are both 
hormonal and non-hormonal, common prescription drugs’ long-term effects are understudied and 
likely even underestimated. Particularly drugs including oestrogens or those altering the 
metabolism of oestrogens may promote carcinogenesis of oestrogen receptor sensitive cancers and 
possibly even lower the risk of sex hormone-associated cancers. Two common examples of such 
prescription drugs are systemic menopausal hormone therapy (MHT) and oral antibiotic treatment.  
Historically, preventive measures have been the key factor in our unending battle against cancer’s 
burden. This doctoral thesis within clinical epidemiology was conducted to evaluate the 
association between exposure to contemporary MHT use and cancer risk (Studies I and II); and 
colorectal cancer mortality (Study IV). These associations were investigated on a population level, 
longitudinally, based on nationwide and population-based cohort studies, taking advantage of the 
unique Swedish prescription feature, including various MHT treatment options. Notably, these 
large-scale cohort studies are feasible to conduct only in a few other countries than Sweden, 
underscoring the importance of valid evidence from methodologically well-grounded studies with 
complete and reliable data sources. Furthermore, Study III aimed to clarify the posed association 
between exposure to oral antibiotic treatment and colorectal cancer risk based on a systematic 
review and dose-response meta-analysis. 
For Studies I, II, and IV, data were retrieved from the Swedish Prescribed Drug Registry, Swedish 
Cancer Registry, Causes of Death Registry, Patient Registry, and the Total Population Registry 
(Study I only). Study I evaluated the net effect of systemic MHT use on cancer risk; and 16 
different cancer types. The findings suggested an association of menopausal hormones with a 
slightly (9%) elevated cancer risk compared with the background population of the same calendar 
period and age. The observed excess risk of cancer was mainly associated with female reproductive 
tract cancers, yet it was almost counterbalanced by the reduced risk of gastrointestinal tract cancers. 
However, the cancer risk varied between the different MHT treatment options and age at treatment 
initiation. Study II was a population-based matched cohort study evaluating the link between ever-
use of MHT and ovarian cancer risk. Whereas ovarian cancer is rare, it is the most lethal of 
gynaecological cancers, owing primarily to late detection, underscoring the need for preventive 
measures. The results suggested that the excess ovarian cancer risk was linked particularly with 
oestrogen combined progestin use, whilst no increased risk was shown among oestrogen-only 
users. Furthermore, cutaneous preparations indicated a possibly less prominent risk than oral 
MHT. Study IV was a nationwide cohort study investigating whether prediagnostic exposure to 
MHT treatment could influence colorectal cancer-specific or all-cause mortality risk among 
women diagnosed with colorectal cancer. The results suggested particularly past users of 
oestrogen-only therapy having a possibly better colorectal cancer survival than women diagnosed 
with colorectal cancer who did not receive menopausal hormones during the study period. 
Study III aimed to explore the posed link between oral antibiotic use with colorectal cancer risk. 
At the time being, the present study was the first systematic review and meta-analysis assessing 
the risk pattern’s shape, considering possible deviation from linearity. The results indicated 
modestly increased colorectal cancer risk, and the association appeared to be related particularly 
with the use of broad-spectrum antibiotics. However, the found dose-response relationship was 
weak, with similar risk patterns within the colorectal continuum.  
In conclusion, the risk of cancer associated with MHT treatment varies between the different 
treatment options and ages. The excess risk is seemingly related to female reproductive tract organ 
cancers, while the risk of gastrointestinal tract cancers appears to be lower, and prediagnostic use 
of MHT might even improve survival from colorectal cancer. Overall, MHT does not seem to 
increase cancer risk if the treatment is initiated near to menopausal onset among women without 
contraindications or high risk of breast, ovarian or endometrial cancer. The found association of 
oral antibiotic treatment with colorectal cancer raises further questions, and notably, the here 
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The long-term effects of common prescription drugs are rarely studied and likely underestimated. 
However, the overall high burden of cancer and a large proportion of prescription drug users 
highlights the importance of considering the use of prescription drugs as a possible risk factor for 
cancer, even if some drugs might seem to have chemopreventive properties, especially for sex 
hormone-associated cancers.(1-4) In Sweden, nearly seven million individuals were exposed to at 
least one common prescription drug in 2017 alone  (±85% of the total population), and virtually 
the entire population is exposed to some drugs during their lifetime.(5) Despite the improved 
antibiotic stewardship, penicillin V remains among the most commonly prescribed drugs in 
Sweden.(5) Furthermore, at least one-third of Swedish women are estimated to require menopausal 
hormone therapy (MHT) to alleviate vasomotor symptoms (VMS), which may diminish the quality 
of life if untreated.(6)  
Whereas it is becoming established that MHT use increases the risk of particularly breast cancer,(7-
10) some evidence advocates oestrogens reducing the risk of colorectal cancer (CRC) similarly to 
other chemopreventive agents like non-steroidal anti-inflammatory drugs and aspirin.(3, 4, 11, 12) 
Although oestrogens possess carcinogenic properties, this could potentially support the preventive 
role of oestrogens, particularly for sex hormone-related cancers,(3, 13-15) or it could imply a part 
of inflammation and infection in carcinogenesis.(16, 17) Furthermore, commonly prescribed 
antibiotics have been linked with elevated colorectal cancer risk and other even more distal 
cancers.(16, 18, 19) One possible explanation could be antibiotic use following changes in the gut 
microbiome composition and alterations in oestrogen’s metabolism,(20-22) - a hypothesis that is 
further supported by the shown microbiome changes among individuals who have been diagnosed 
with colorectal cancer.(16)  
This doctoral thesis within clinical epidemiology aims to investigate the role of two common 
prescription drugs on the risk of cancer and cause-specific mortality, evaluated on a population 
level. Specifically, this thesis aims to evaluate the association of systemic MHT use on cancer risk 
and colorectal cancer mortality; and clarify the posed association between oral antibiotic treatment 
and colorectal cancer risk. The specific knowledge gaps and novelty of the studies included in this 
thesis are presented in Table 1. The obtained results may provide valuable information to aid in 
clinical risk assessment, identifying MHT treatment options, which may include less excess risk 




2 LITERATURE REVIEW 
2.1 KNOWLEDGE GAPS AND NOVELTY 
 
Table 1.  A selected overview of identified knowledge gaps and scientific novelty of the studies at 
the time each study was initiated. 
 What is already known? Identified knowledge gaps The scientific novelty at the time of 
study initiation 
Study I Menopausal hormone therapy 
(MHT) is still the only evidently 
effective prescription drug to 
alleviate the core symptoms of 
menopause. However, the total 
cancer risk associated with MHT 
use is incompletely understood. 
 
1. What is the total risk of cancer 
associated with contemporary use 
of MHT? 
 
2.What is the risk of the major 
cancer types? 
 
3. Are there differences between 
various MHT treatment options? 
 
This was the first sufficiently 
powered population-based cohort 
study evaluating the net effect of 
MHT use on cancer risk.  
  
 
Study II  Ovarian cancer has a poor 
prognosis, owing to diagnostic 
delay and treatment resistance.  
Menopausal hormone therapy 
might increase ovarian cancer 
risk, yet many prior studies have 
been small with limited power. 
Evidence is sparse to determine 
whether the risk could differ by 
administration route of MHT 
treatment.  
1. Does the risk of ovarian cancer 
vary between the various MHT 
treatment options prescribed in 
Sweden? 
 
2. Does the risk differ by age at 
treatment initiation? 
 
3. What is the risk among current 
and past users? 
 
4. Does the risk change by 
administration route of MHT? 
 
This was one of the largest 
population-based studies 
investigating the association between 
contemporary MHT use and ovarian 
cancer risk, taking advantage of the 
multiple MHT treatment options 
available in Sweden. 
 
Study III  The gut microbiome may alter 
oestrogens’ metabolism. Oral 
antibiotic treatment may lead to 
dysbiosis, possibly promoting 
inflammation and changing the 
microbiome’s composition and 
even functions. 
Exposure to systemic oral 
antibiotics has been linked with 
an elevated colorectal cancer 
(CRC) risk, yet it is unclear if this 
posed association may vary within 
the colorectal continuum. 
 
1. Does the risk of CRC differ 
within the colorectal continuum? 
 
2. Does the risk vary between 
broad- and narrow-spectrum 
antibiotics? 
 
3. What is the shape of the risk 
pattern? 
 
4. What is the overall association 
between oral antibiotics with CRC 
risk? 
 
This was the first dose-response 
meta-analysis to date of publication, 
addressing whether a potential dose-
response relationship could depart 
from linearity. This was also the 
largest meta-analysis investigating 
whether the posed link could differ 
between broad- and narrow-spectrum 
antibiotics. 
 
Study IV Evidence suggests that MHT use 
could lower CRC risk, yet fewer 
studies have focused on the 
association with mortality. While 
the prognostic outlook could be 
even better among women who 
received MHT before their CRC 
diagnosis, current evidence is 
inconclusive. 
 
1. What is the association of 
prediagnostic use of MHT with 
CRC-specific mortality and all-
cause mortality risk? 
 
2. Do these potential associations 
vary by the different MHT 
treatment options? 
This was one of the largest 
population-based cohort studies, 
including virtually all Swedish MHT 
users diagnosed with CRC during the 
study period, estimating the influence 
of MHT use before CRC diagnosis 




2.2 BACKGROUND  
Despite surgical advances and improved treatments options,(23-25) cancer remain the leading cause 
of death globally.(24, 26, 27) In 2018 alone, malignant neoplasms accounted for almost 10 million 
deaths, underscoring the high burden of the disease, highlighting the need for preventive 
measures.(26, 27) Among women, cancer of the breast and colorectal continuum are the most 
common cancer types globally.(23, 24, 26, 28) Whereas the risk factors are both hormonal and non-
hormonal,(16, 29-31) emerging body of evidence suggests that the widespread use of common 
prescription drugs might be associated with carcinogenic risk, progression of solid tumours, and 
possibly even cancer survival.(9, 16, 31, 32)  
2.2.1 Cancer - the leading cause of death 
More than half of all deaths occurring globally (60%) are cancer-related,(24, 26, 27) in spite of 
advanced treatment options and implemented population-level or regional screening programs.(23, 
24, 33) Paradoxically evidence suggests that around about 30-50% of all cancers could potentially 
be prevented, mainly owing to modifiable risk factors, and earlier detection due to implementation 
of screening programs.(26, 33) These facts not only highlight the pivotal role of preventive measures 
but also underscore the importance of identifying potential risk factors, as naturally, to prevent 
cancer, one must first identify possible risk factors contributing to carcinogenesis.(25, 34, 35)  
2.2.2 Pharmacoepidemiology 
Compared with other outcomes such as cardiovascular diseases, where the effect of drugs can be 
expected to be relatively immediate, cancer development requires a substantially longer latency 
period. Therefore, any meaningful investigation of a possible association of prescription drugs with 
cancer promotion, progression, or potentially preventive effect should be evaluated longitudinally 
over time. This requires i) long-term exposure, ii) more extended latency period over time, iii) large 
sample size, and iv) most importantly, the study should be conducted without exposing healthy 
individuals to any excess risk or potentially harmful side effects.(36) Unequivocally, addressing this 
type of research by conducting a randomised controlled trial (RCT) would be ethically unjustifiable. 
However, observational pharmacoepidemiological studies based on real-world data and settings 
allow the evaluation of various drugs and their effects in a prospective cohort with sufficient follow-
up time. Besides, large-scaled nationwide and population-based cohort studies,(37-40) facilitate the 
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statistical power, enhancing the generalisability of the results,(36) without exposing healthy 
individuals to any excess risks.  
Against a common misconception, some of the conducted trials might be underpowered, leading to 
imprecise estimates, which might be challenging to reproduce. Additionally, trials like observational 
studies are often limited to specific populations,(36, 38, 41) introducing some type of selection. 
However, real-world data gathered from valid registries on a population level may even reflect the 
current clinical praxis to a greater extent than trials. Well-designed registry-based observational 
studies might include a more pronounced variety of participants, enhancing the obtained results’ 
generalisability. 
2.3 CANCER EPIDEMIOLOGY 
Breast cancer is a major health threat globally, accounting for one-fourth of all incident cancers.(23, 
24) In 2018, over 28,000 Swedish women were diagnosed with cancer, breast cancer remaining the 
leading cause of cancer-associated deaths among middle-aged women, accounting for one-third of 
all female cancers.(33, 42) Of other female reproductive organ tract cancers, 10% are gynaecological 
cancers (±48% endometrial, 26% ovarian, and 16% cervical cancer). Ovarian cancer, although rare, 
is the most fatal of gynaecological cancers, particularly in high-income countries.(25, 35, 43, 44) The 
prognosis is poor, with 5-year relative survival of less than 50 % and an expected 10-year survival 
below 40 %, owing to late detection, lack of modifiable risk factors and increasing treatment 
resistance.(35, 43, 44)  
Colorectal cancer is among the top three most common cancers globally, and it is the second most 
common cause of cancer-associated deaths among both sexes, summing up to 10% of all cancer-
related deaths. Overall, gastrointestinal tract cancers account for almost a quarter of the cancer deaths 
worldwide,(45, 46) and the upper-gastrointestinal cancers, except for gastric cancer, are listed within 
the global top ten cancer deaths.(28) Whereas the overall incidence of colorectal cancer is seemingly 
declining, especially in high-income countries,(45, 46) an incidence increase has been noted across 
several continents, particularly among individuals younger than 40-50 years. Notably, whereas 
younger age is usually a favourable factor, some evidence indicates that these malignancies among 
the younger people may even have a poorer prognosis.(47-50)  
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2.3.1 General risk factors 
Although environmental, behavioural, and genetic predisposition unarguably contributes to a large 
proportion of cancer cases, these factors alone should not explain the globally increasing burden of 
cancer.(26, 29) Whilst the aetiology naturally differs between various cancer types, and for some 
malignancies, the underlying mechanisms are incompletely understood; in general, the risk factors 
are hormonal and non-hormonal.(3, 25, 29, 34, 51) 
Infection is one of the well-known risk factors for cancer and a major global health concern, 
contributing up to one-fourth of the diagnosed cancers annually, with somewhat lower impact in 
high-income countries.(30, 52) Whilst the evidence for bacterial infections is less clear, several viral 
infections are associated with an elevated cancer risk. A classic example of viral infection influencing 
cancer risk is Helicobacter pylori and gastric cancer, and certain specific strains of the Human 
papillomavirus and cervical cancer.(30, 52) Whereas no specific pathogens are firmly confirmed for 
breast cancer,(53, 54) some strains of Escherichia coli and Fusobacterium nucleatum are suggested 
promoting development and possibly even prognosis of colorectal cancer, potentially involving a 
worse prognosis.(55-57)  
2.3.2 Ovarian cancer  
Among a family history of ovarian cancer, gene mutations in Breast Cancer gene 1 and 2  (BRCA1/ 
BRCA2) are well-established risk factors for ovarian cancer.(58) Other risk factors associated with 
higher ovarian cancer risk are endometriosis, current tobacco use, infertility, menopausal hormones, 
increasing age, and age at menopause.(43, 59) In contrast, parity, breastfeeding, oral contraceptive 
use, and tubal ligation are linked with reduced ovarian cancer risk.(60) Notably, all of these factors 
apart from tubal ligation are linked to anovulation and thus connected with a lower cumulative 
number of ovulatory circles during lifetime.(59) 
2.3.3 Colorectal cancer  
Several well-confirmed risk factors are identified for colorectal cancer including, a family history of 
colorectal cancer, adenomas, and serrated polyps, increasing age, and untreated inflammatory bowel 
disease.(61, 62) Other risk factors include male sex, Westernized diet, and sedentary lifestyle, all 
associated with slight to modestly increased colorectal cancer risk. However, some evidence suggests 
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that up to 70% of colorectal cancers might be related to dietary factors,(62) which could further 
support the gut microbiome’s role in the formation and progression of colorectal cancer.(55-57)  
In contrast, colorectal cancer screening is linked with diminished colorectal cancer risk and possibly 
even mortality due to earlier detection of cancer and polyps.(61) Furthermore, prescription drugs that 
either include or alter oestrogens’ metabolism are suggested to have a pivotal role in potentially 
reducing the risk of sex hormone-related cancers.(63)  
2.4 THE ROLE OF OESTROGENS  
Hormones, in general, contribute to the expected growth of various tissues among both women and 
men, and they may influence the behaviour and metabolism of cells. A common hallmark featured 
for all cancer progression includes uncontrolled cellular proliferation, and modified metabolism.(64)  
Oestrogens either can directly induce cellular proliferation, or oestrogen metabolites may stimulate 
mutations. Common to both of these pathways is that they ultimately lead to an increased cell 
division, thus increasing the possibility of mutations to occur.(64) Therefore, oestrogens might 
stimulate cancer promotion and progression of solid tumours, possibly playing a pivotal role in the 
aetiology of particularly oestrogen sensitive cancers. Some of these cancer types are globally 
common, such as breast cancer, while other cancer types such as ovarian cancer are rare with a 
nonetheless poorer prognosis, highlighting the need for preventive measures and early detection. 
However, the effect of MHT is strikingly different in breast and endometrial tissue, varying across 
the different MHT types.(7, 9, 65, 66) Consequently, it is essential to cautiously evaluate the 
influence of various MHT treatment options on cancer risk. 
2.4.1 Potential underlying mechanisms 
The role of oestrogens in cancer development is undoubtedly complex.(4) Whilst oestrogens are 
considered to have carcinogenic properties, in contrast, they might be protective of particularly sex 
hormone-associated cancers.(13, 14, 46, 67-69) The effect of oestrogens is believed to be mediated 
by two different nuclear receptors, oestrogen receptor alpha (ERα) and beta (ERβ),(63) and especially 
ERβ associated pathways are likely involved in the underlying pathophysiology. Oestrogen receptor 
beta promotes pro-apoptotic signalling, particularly in the colon, inhibiting inflammatory signalling, 
and progression of colorectal cancer is associated with loss of ERβ expression. (70, 71)  
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In experimental mouse models, ERβ in normal colon epithelia has been associated with a reduced 
inflammation of the gut,(72) likely by promoting pro-apoptotic signalling and thereby reducing the 
formation of a tumour. Besides, exogenous oestrogens have been suggested to influence 
inflammatory markers, reducing crypt’s proliferation,(72, 73) and changes in the gut microbiota’s 
diversity among colorectal cancer-induced male mice.(63) Evidence indicates oestrogens modifying 
the microbiome, and as discussed above, oestrogens appear to influence the inflammation of the 
colon as well. Experiments are required to determine if these changes in the microbiome are for the 
better or not. In terms of colorectal cancer risk, oestrogens are suggested to be protective, but whether 
this is because of the gut microbiome changes is not yet determined. However, considering that this 
proposed association of oestrogens with the gut microbiome might be modifiable, it could contribute 
to lower colorectal cancer risk,(63) and potentially even better prognostic outlook among individuals 















2.5 MENOPAUSAL HORMONE THERAPY 
 
 
Scientific illustration by INA SCHUPPE KOISTINEN ©, www.inasakvareller.se 
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2.5.1 One of the most controversial drugs invented 
Menopausal hormones were among the most frequently prescribed drugs in the United States in the 
1990s, and MHT is still the most effective licensed pharmacological treatment against vasomotor 
symptoms, which constitute the cardinal menopausal symptoms.(74) However, MHT has been 
described as probably one of the most controversial drugs ever invented, owing to the controversy of 
observational studies contra randomised controlled trials.(75) It is hardly feasible to even mention 
menopausal hormones without at least shortly referring to the Women’s Health Trial conducted in 
the United States shortly after the millennium – a landmark ending the popularity era of MHT.(6, 9) 
The Trial found a 24% increased breast cancer risk among participants receiving postmenopausal 
conjugated equine oestrogens combined with medroxyprogesterone acetate.(9) The initially shown 
association of combination therapy with increased risk of invasive breast cancer remained in post-
trial evaluation,(76) and the association with breast cancer has been confirmed in previous and recent 
epidemiological studies.(7, 77) 
In the context of menopausal hormones, observational studies are often associated with a healthy user 
bias, healthy continuer bias, and even a prescriber effect.(75) However, it is noteworthy how several 
essential factors, such as women’s age at trial entry and type of MHT treatment, are all too often 
dismissed when generalising the trial results to other populations and settings. A challenge worthy 
of discussion is that the Women’s Health Trial evaluated the effect of conjugated equine oestrogens 
and their combination with medroxyprogesterone acetate, whereas oestradiol is the most prescribed 
oestrogen formulation in Europe,(6, 76) inherently challenging direct comparisons.  
2.5.2 Prescription patterns 
Before the 1990s, Sweden was one of the top European consumers of menopausal hormones, with 
over 30% of users with a median duration of four years. Around the millennium, nearly 40 million 
daily-defined doses were prescribed annually.(78, 79) The number of prescriptions dropped after 
studies reporting an increased risk of deleterious health effects, including a higher risk of invasive 
breast cancer and cardiovascular events.(9, 80-85) By 2005, the daily-defined doses had halved down 
to 20 million. Per contra, no immediately evident decline in the breast or gynaecological cancer 
incidence was noted following the drop of MHT prescriptions in Sweden, as shown in Figure 1. 
However, caution should be taken due to changes in dose recommendations and formulations over 
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the past decades, which challenges comparisons and could even make them misrepresentative.(78, 
79, 82, 86) 
Nonetheless, valid concerns have addressed that many women with moderate to severe symptoms of 
menopause may be left untreated out of fear of the association with cancer.(6, 81, 87) Whereas under-
treatment not only influences the individuals’ health negatively, it may also provide market 
opportunities for less serious treatment options,(6) without proper follow-up or without being 
licensed by the Swedish Medical Products Agency.  
 
 
Figure 1. Age-standardised cancer incidence among women aged 40 to 74 years, and the number of 
here investigated dispensed drugs, between 2006 and 2018 in Sweden. Data were retrieved from the 
National Board of Health and Welfare (https//: www.socialstyrelsen.se). Abbreviations: MHT: 
menopausal hormone therapy, AB: antibiotic treatment, Ovaries: ovarian cancer, Gynecology: all 
gynaecological cancers, Breast: breast cancer, Gastrointestinal tract: cancers of the gastrointestinal 




2.5.3 Treatment indications 
Currently, the primary indication for menopausal hormone therapy is alleviating vasomotor 
symptoms, and menopausal hormones are not advocated for the prevention of chronic diseases.(4, 
88, 89) The cardinal VMS symptoms include hot flushes and night sweats, affecting sleep, mood, 
and quality of life significantly. They are experienced by 50% up to 80% of women, possibly with 
some variation of the frequency across different ethnicities.(74)  
Treatment initiation is recommended before 60 years of age or within ten years from menopausal 
onset.(90, 91) In general, treatment duration longer than five years is not advisable, yet some women 
may benefit from substantially longer treatment duration. Nonetheless, persistent vasomotor 
symptoms have been linked with an increased breast cancer risk,(92) warranting for a thorough 
individual risk-benefit assessment.(4, 6, 82, 87, 93, 94) 
Whereas women with an intact uterus should receive only oestrogen combined progestin therapy 
(EP-MHT) to counteract unopposed oestrogens (E-MHT) associated risk of endometrial hyperplasia, 
the link between combination therapy and risk of breast cancer contra endometrial cancer is 
compelling.(7, 9, 95, 96) However, evidence is limited whether the association of menopausal 
hormones with the risk of cancer could vary between the different treatment options, and the net 
effect of MHT on cancer risk is understudied. Given as many as every third Swedish woman is 
expected to require MHT to alleviate the vasomotor symptoms,(6)  it highlights the need to 
thoroughly investigate which treatment options could be safest, involving less excess risk of cancer.   
2.5.4 Systemic versus local treatment 
The indications for systemic versus local MHT treatment are different. Whilst systemic MHT is 
prescribed for the cardinal symptoms of menopause (id est vasomotor symptoms), local preparations 
such as vaginal creams are prescribed primarily for vulvovaginal atrophy. This thesis focuses on the 
contemporary use of systemic MHT, excluding the local treatments which should not be expected to 
have systemic effects.(97) This thesis included orally and transdermally administered systemic MHT 
preparations. Vaginal mucosa should be thicker compared to skin, and therefore, the vaginal 
preparations should not be absorbed into the bloodstream. Besides, any potentially absorbed amount 




2.5.5 Oral versus transdermal treatment  
Whereas oral and transdermal menopausal hormones effectively alleviate vasomotor symptoms, 
evidence indicates transdermal MHT involving a lower risk of cancer and other deleterious health 
effects, particularly thromboembolic events.(84, 85, 98) Transdermal MHT (id est gels, creams, and 
patches) requires a lower effective dose, as they are absorbed to the microcirculation, closely 
mimicking natural hormones and avoiding the first-passage in the liver.  In comparison, oral MHT 
requires a higher dose following the significant loss of bioavailability due to the first-pass liver 
metabolism.(84, 98)  While the harmful effect of oral MHT on venous thromboembolism risk appears 
to be associated peculiarly with medroxyprogesterone acetate, (84) less is known whether the 
association of transdermal MHT on the risk of cancer could vary between the different MHT types. 
2.5.6 A unique feature of Swedish prescriptions 
A distinguishing feature for prescriptions of MHT in Sweden is the availability of various treatment 
options and, in particular, the use of continuous and sequential combination therapy regimens. 
Combined with the valid high-quality Swedish health data registries, this offers a unique opportunity 
to investigate whether the association of contemporary MHT use and cancer risk may differ between 
the various MHT treatment options, based on longitudinal, large, and population-based cohort 
studies. Nonetheless, this unique Swedish feature also brings along several challenges. As mentioned 
earlier, comparisons to other studies conducted in countries with different MHT preparations and 
treatment options are complex. The doses and formulations have changed over time, and several of 
the MHT treatment options could be metabolised differently.(98)  
2.5.7 Link with cancer 
Even though menopausal hormones have been used over a half-century, its association with cancer 
remains inconclusive, requiring re-evaluation.(8, 9, 32, 99-102) Overall, it is becoming established 
that MHT use, in particular combination therapy, is linked with elevated breast cancer risk, whereas 
unopposed oestrogen-only therapy is associated with increased endometrial cancer risk.(8-10, 77, 96, 
103, 104) The association with ovarian cancer is less clear.(105, 106) Per contra, a lower risk has 
been suggested for mainly male-dominant cancers such as cancers of the gastrointestinal tract, 
including oesophageal, biliary tract and pancreatic cancer.(12, 14, 15, 100, 107-110) Sparse evidence 
indicates a possible link between MHT use and central nervous system tumours.(111)  
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Whereas the mechanism of oestrogens for especially breast and endometrial cancer progression may 
be linked with increased cellular proliferation,(96) oestrogens do not seemingly pose direct effects 
on epithelial cells of the ovaries. However, ovulations are stimulated by hormones and followed by 
cellular proliferation, and a more significant number of cumulative lifetime ovulatory circles are 




















2.6 ORAL ANTIBIOTIC TREATMENT AND RISK OF COLORECTAL CANCER  
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2.6.1 The global pandemic of antibiotic resistance  
Antibiotics were developed back in the 1940s, and ever since, they have contributed to saving many 
lives. However, estimates suggest up to half of all prescribed antibiotics potentially being prescribed 
unnecessarily for non-indicated conditions.(112) Notably, this phenomenon contributes to the rise of 
new novel pathogen bacteria, fuelling the ongoing pandemic of global antibiotic resistance.(113, 114) 
Whereas Sweden has a somewhat more conservative prescription pattern of antibiotic treatment 
compared to several other European countries, approximately 20-50% of the world’s population are 
annually exposed to antibiotics.(115-118) 
2.6.2 Antibiotics, gut microbiome, and cancer 
2.6.2.1 The gut microbiome 
Typically, a healthy gut microbiome has several vital roles. These pivotal roles include reducing 
inflammation, producing essential vitamins, and functions related to oestrogen metabolism. An 
emerging body of evidence antibiotics changing the gut microbiome composition,(20-22) leading to 
a state known as dysbiosis and possibly altering important functions of the gut microbiome.(20, 119-
121) Among some individuals, these effects of antibiotic treatment on the gut microbiome might be 
persistent or even permanent, allowing colonization with pathogens, and facilitating local 
inflammation and possibly even carcinogenetic events.(16, 29) 
2.6.2.2 Antibiotics and oestrogens 
Exposure to systemic oral antibiotic treatment has been posed as a risk factor for increased colorectal 
cancer risk,(18, 19, 122) and even more distal tumours such as breast cancer.(18, 31, 123) Whilst 
confounding by indication should be taken into consideration, it is biologically plausible that the 
impact of systemic antibiotic treatment on the gut microbiome could differ between broad- and 
narrow-spectrum antibiotics. In brief, broad-spectrum antibiotics could theoretically wipe out more 
of the normal gut microbiota, allowing for colonization with new pathogens, and potentially 
influencing the posed cancer risk to a greater extent as compared with narrow-spectrum antibiotics. 
Furthermore, the gut microbiome alterations shown among patients diagnosed with colorectal cancer 
may further imply the host-microbiome relationship’s possible role. Additionally, antibiotics alter 
the metabolism of endogenous oestrogens, which could influence the risk of especially sex hormone-
related cancers.(16, 29, 107) In fact, some data suggests that oestrogens and other chemopreventive 
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drugs such as non-steroidal anti-inflammatory drugs and aspirin could lower the colorectal cancer 
risk,(11, 105) which potentially indicates for inflammation’s role in the formation of colorectal 
cancer.(16) 
2.6.2.3 Posed cancer risk 
The number of dispensed antibiotic prescriptions among Swedish women aged between 40 to 74 
years has somewhat declined since 2012 (Figure 1), most likely owing to improved antibiotic 
stewardship. However, no apparent decline was seen in the incidence of gastrointestinal tract cancers. 
There are significant knowledge gaps and a scarcity of solid evidence confirming the posed 
carcinogenic risk associated with exposure to oral antibiotic treatment and colorectal cancer risk. In 
specific, there is an unmet need for valid research to evaluate whether the risk of colorectal cancer 
might vary within the colorectal continuum or between the various antibiotic classes, in particular 
among broad- and narrow-spectrum antibiotics. Most importantly, none of the previously conducted 
meta-analyses has considered a departure from linearity,(18, 50, 124) although this is crucial to better 
understanding the shape of the potential risk pattern. A simple binary categorization to low versus 
high dose exposure to antibiotics could easily lead to loss of essential data, highlighting the value of 




3 RESEARCH AIMS  
3.1 THE OVERALL AIM OF THE THESIS 
This thesis aims to evaluate the association of two common prescription drugs on the risk of cancer. 
Specifically, this doctoral thesis aims to investigate the association between contemporary use of 
systemic MHT and the risk of cancer, its influence on colorectal cancer mortality, and clarify the 
posed association of oral antibiotic treatment with colorectal cancer risk. 
Our primary hypothesis is that pharmacological treatment with prescription drugs, which either 
include oestrogens or may alter oestrogens’ metabolism, might reduce the risk of sex hormone-
associated cancers. For these cancer types, the prognostic outlook could potentially be even better 
among drug users than individuals who did not receive the drug.  
3.2 SPECIFIC AIMS OF THE INCLUDED STUDIES  
 
• To evaluate the total cancer risk among contemporary MHT users, compared to the 
Swedish background population.   
• To assess the association between contemporary MHT use and ovarian cancer risk, 
evaluating which MHT treatment options may include less excess risk of cancer.   
• To investigate the association between prediagnostic MHT use and risk of cause-specific 
and all-cause mortality among women diagnosed with colorectal cancer. 
• To clarify the link of oral antibiotic treatment with risk of colorectal cancer through a 





4 MATERIALS AND METHODS 
4.1 OVERVIEW 
An overview of the methods applied in studies I-IV is presented in Table 2. 
Table 2. A selected overview of the methods in studies I-IV. 
 Study I Study II Study III Study IV 










Data sources  The Swedish Prescribed 
Drug Registry, Cancer 
Registry, Causes of 
Death Registry, and 
Registry of the Total 
Population 
The Swedish Prescribed 
Drug Registry, Patient 
Registry, Cancer Registry, 
and Causes of Death 
Registry 
PubMed, Web of 
Science, Embase, and 
The Cochrane Library 
The Swedish Prescribed 
Drug Registry, Patient 
Registry, Cancer Registry, 
and Causes of Death 
Registry 
Study Period  2005-2012 2005-2012 From inception up to 
February 2020 
2006-2014  
Inclusion Women, at least 40 years or older at first recorded 
menopausal hormone therapy (MHT) prescription, 
who had received at least one prescription of systemic 
MHT during the study period 
Individuals who ever 
used antibiotics 
 
Women diagnosed with 
colorectal cancer who had 






The net effect on cancer Ovarian cancer  Colorectal cancer  Colorectal cancer-specific 
















events, year of birth, 
smoking-related diseases, 
alcohol-related diseases, 
obesity, diabetes mellitus, 
and osteoporosis 
 
As reported in the 
original publications  
 
Hysterectomy, ever-
parous, thrombotic events, 
age at diagnosis, smoking-
related diseases, alcohol-
related diseases, obesity, 
diabetes mellitus, 
osteoporosis, cancer site, 
and stage of cancer 
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4.2 REGISTRY-BASED DATA SOURCES 
An overview of the national registries used in the thesis included studies is presented in Figure 2. 
Data was ordered and received from the Swedish National Board of Health and Welfare, following 
a beforehand approved ethical application and a detailed a priori established study protocols for 
each of the studies included in this thesis.  
Studies I, II, and IV were based on the high-quality Swedish registries with nationwide coverage 
of healthcare and other administrative data. The unique Swedish personal identity number ensured 
a valid and unambiguous linkage of data between the various registries. This personal 
identification number has been allocated to all Swedish residents since 1947. The Swedish 
National Tax Board, operating under the Swedish National Board of Health and Welfare’s 
supervision, manages the identification number.(125-127) The Swedish Registry of Total 
population was established in 1749, yet incorporated into the Swedish Tax Office in 1962. 
However, the Population Registry is maintained by Statistics Sweden.(127, 128)  
 
Figure 2. An overview of the Swedish registries used in the studies included in this thesis. 
Abbreviations: ATC: Anatomical Therapeutic Chemical code, ICD-code: International 




4.2.1 Database for the registry-studies  
To investigate the association of various MHT treatment options with the cancer risk and colorectal 
cancer mortality, we gathered a large cohort including virtually all Swedish women who had 
received at least one dispensed prescription of systemic MHT between July 2005 and December 
2014 as identified from the Swedish Prescribed Drug Registry. This cohort of women was singled 
out from a database including over 7.5 million unique Swedish residents, covering more than 85% 
of the Swedish population, making it one of the largest cohorts globally to investigate prescription 
drugs’ association with cancer-related outcomes. 
The initial database included all unique residents who had received at least one dispensed 
prescription of a priori selected drugs (id est MHT, proton pump inhibitors, Helicobacter pylori 
eradication treatment, aspirin, and other non-steroidal anti-inflammatory drugs, statins, or 
bisphosphonates), as ascertained from the Swedish Prescribed Drug Registry.  
The database had very high coverage of women at peri- and postmenopausal age. Over 90% of 
women aged 40-64 years and over 95% of women who were 65 years or older were included in 
the cohort.(7) Figure 3 presents the initial cohort selection for Studies I, II, and IV. We only 
included women 40 years or older at the first recorded prescription date, excluding premenopausal 
women or individuals receiving menopausal hormones for other indications. Notably, the Swedish 
Prescribed Drug Registry was established first in July 2005. Thus, our data for prescription drugs 
started from July 2005.(125) Furthermore, considering previous cancer or cancer treatment could 
have influenced the results, all women with previous malignancy, apart from non-melanoma skin 











Figure 3. The initial cohort selection of women exposed to menopausal hormone therapy (MHT), 










4.2.2 The Swedish Prescribed Drug Registry 
The Swedish Prescribed Drug Registry was established in July 2005, and it is held at the Centre 
for Epidemiology at the National Board of Health and Welfare, operating under legislation issued 
by the Swedish government (SFS 2005:363).(125) The National Corporation of Swedish 
Pharmacies is responsible for the data collection, and information on dispensed prescriptions is 
reported monthly to the Centre for Epidemiology.(125) 
The Prescribed Drug Registry covers virtually all outpatient care prescribed and dispensed drugs 
for all Swedish residents. Patient data are missing for less than 0.3% of all items. Prescribed drugs 
are entered into the Registry using Anatomical Therapeutic Chemical (ATC) classification codes 
(including substance, formulation, brand name, and package et cetera), and the Drug Registry 
includes data such as age, sex, number of prescribed prescriptions, date of prescribing and 
dispensing, dispensed amount and dose.(125) Whilst data on inpatient care used drugs is not 
included in the registry, menopausal hormone therapy is less likely prescribed in inpatient care 
settings. Thus, the coverage of the dispensed MHT prescriptions in the thesis included studies 
should be high. Noticeably, injectable, or over-the-counter sold MHT are not available in Sweden. 




Table 3. Menopausal hormone therapy treatment options considered in this thesis. The subgroup 
presents the classification of oestrogen formulations. Abbreviations: ATC code: Anatomical 









Type of therapy Formulations/derivatives  Subgroup ATC code 
Oestrogen-only Oestradiol (E2) 1 G03CA03 
 
Ethinylestradiol 1 G03CA01 
 
Oestriol (E3) 2 G03CA04 
 
Conjugated estrogens 3 G03CA57 
 
Other mixed  4 G03F 
Tibolone only Tibolone 
 
G03CX01 




Sequential preparations (SP) 
 
G03FB 
Progesterone derivatives  
(Including natural progesterones) 




Medroxyprogesterone combined oestrogen CC G03FA12 
 






Dydrogesterone  G03DB01 












Norethisterone combined oestrogen CC G03FA01 
 
Dienogest combined oestrogen CC G03FA15 
 
Noretisterone combined oestrogen SP G03FB05 
 
Levonorgestrel combined oestrogen SP G03FB09 




4.2.3 The Swedish Cancer Registry 
The nationwide Swedish Cancer Registry was founded in 1958. Clinicians and pathologists are 
obligated by the Swedish law to report all new cancer cases to the Registry, and data is entered 
using International Classification of Disease (ICD) codes. Besides the date of diagnosis, 
information of the tumour type, site, and histology is recorded.(116, 125) The Registry has high 
completeness, with some variation across cancer types. Yet, preceding validation studies indicate 
a very high overall completeness (over 96%) and concordance.(116) 
4.2.4 The National Causes of Death Registry 
The Swedish Causes of Death Registry was established in 1952. Since 1984 and onwards, it has 
been held at the National Board of Health and Welfare. The Registry is 100% complete for deaths 
occurring in Sweden and records the date of death, cause of death, underlying causes of death, et 
cetera using ICD codes.(125, 129)  
4.3 ELECTRONIC DATABASES  
4.3.1 Published literature  
Study III was a systematic review and dose-response meta-analysis for which the data was 









4.4 STUDIES ON MENOPAUSAL HORMONE THERAPY 
4.4.1 Study I 
4.4.1.1 Design 
This was a nationwide and population-based cohort study with the primary aim of estimating the 
net effect of contemporary use of systemic MHT on the total cancer risk compared with the entire 
Swedish female general population. The secondary aim was to investigate the association between 
MHT use and risk of 16 different cancer types based on the incidence and mortality of cancer.(28, 
130) The large-scaled and population-level design inherently increased the sample size, enabling 
the evaluation of various MHT treatment options and even more rare outcomes.  
4.4.1.2 The cohort and follow-up 
The cohort included virtually all Swedish MHT ever-users (N=290,186), who were 40 years old 
or older at first recorded prescription, and who had received at least one dispensed prescription of 
systemic MHT between 1 July 2005 and 31 December 2012, as ascertained from the Swedish 
Prescribed Drug Registry based on ATC codes. Non-users of menopausal hormones consisted of 
the entire Swedish female population at the same calendar period and age. The Swedish Cancer 
Registry was used to ascertain all cancer cases during the study period, classified by ICD 7th and 
crosschecked with the ICD 10th edition (Study I, eTable 1). Women with a history of malignancy, 
apart from non-melanoma skin cancer, were excluded before cohort enrolment. 
4.4.1.3 Statistical methods  
The relative risk of cancer was estimated by calculating standardised incidence ratios (SIRs) with 
95% confidence intervals (CIs). The observed incidence of cancer among women exposed to 
menopausal hormones was divided by the expected cancer incidence among the entire Swedish 
female background population. We stratified the analyses by women’s age at the start of the 
treatment (<60, 60-69, and ≥70 years), according to the recommended age for MHT initiation and 
cessation,(90, 91, 131) calendar period (2005-2006, 2007-2009, and 2010-2012), and MHT types. 
Women who received only E-MHT prescriptions were classified as oestrogen-only therapy users; 
those receiving one or more combination therapy prescriptions during the study period were 
considered EP-MHT users. Women were followed from the first prescription date until cancer 
development, death, or end of study (31 December 2012), whichever occurred first. Changes in 
the calendar periods and age groups were considered. The linear effect of age on cancer risk was 
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assessed using a score test for trend. Furthermore, to evaluate a possible influence of MHT type 
on the risk of cancer, we performed a regression with an interaction term, and statistical 
significance was tested with a Wald-test (alpha level set to 0.05). The first calendar period (2005-
2006) was excluded from the sensitivity analyses. For analyses on the duration of use, treatment 
duration was categorized as having received menopausal hormones for <1, 1-2, 3-4, and ≥5 years 
based on daily-defined doses.  
4.4.2 Study II 
4.4.2.1 Design 
This was a prospective population-level matched-cohort study investigating the association 
between contemporary use of MHT and the risk of ovarian cancer (ICD-7 codes 175.01, 9 
crosschecked with ICD-10 codes C56, C57. 0-4, 7, 9) compared with women who did not receive 
MHT during the study period (2005 – 2012). 
4.4.2.2 The cohort and follow-up 
The Swedish Prescribed Drug Registry was used to identify all Swedish MHT users who were at 
least 40 years old at the first recorded prescription and had received at least one dispensed 
prescription of systemic MHT (N=288,950), between 1 July 2005 and 31 December 2012, as 
ascertained from the Swedish Patient Registry. Ever-users of MHT were group-level matched (1:3) 
to 866,546 women not receiving MHT during the study period. Firstly, we stratified women by 
three binary variables which may influence MHT prescription (id est hysterectomy, thrombotic 
events, and parity), and within each stratum, the exposed women were matched to the nearest 
neighbour (who did not receive MHT) on the year of birth, and main comorbidities (id est smoking- 
and alcohol-related diseases, diabetes, and obesity) based on discharge diagnoses (Patient 
Registry).(7) Women with a record of oophorectomy or tubal ligation were excluded to avoid 
misclassification, as identified from the Swedish Patient Registry.  
4.4.2.3 Statistical analyses 
Conditional multivariable logistic regression models providing odds ratios (ORs) with 95% 
confidence intervals were used to estimate the relative risk of ovarian cancer.(132) The estimates 
were adjusted for all the eight matching variables and osteoporosis (id est confounding by 
indication). Because the group-level matching aims to balance out the effect of follow-up time 
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between the groups, a conservative approach was chosen without assigning any substitute date for 
the non-exposed women to address the duration of MHT use. 
All analyses compared ever-users of systemic MHT with women who did not receive menopausal 
hormones during the study period, and the analyses were stratified by age at treatment initiation 
(<60 years, 60-69, and ≥70 years). Exposure to MHT was classified based on ATC codes, and the 
various MHT treatment options were sub-grouped by MHT types, oestrogen formulations, and EP-
MHT regimens. Here, tibolone users were separated from E-MHT users to investigate any 
potential differences associated with ovarian cancer risk. Women who changed MHT treatment 
during the study period were excluded from the sub-group analyses.  Moreover, MHT users were 
classified into ever, current, and past users. Women who had received at least one dispensed 
prescription during the last six months of the follow-up were classified as current MHT users. All 
other women were classified as past MHT users. 
4.4.3 Study IV 
4.4.3.1 Design 
This was a nationwide population-based cohort study within a larger population-based matched 
cohort, which is described in extensive detail elsewhere.(7) From the source cohort, we included 
all Swedish MHT ever-users and the group-level matched non-users who developed colorectal 
cancer between 2006 and 2012, ensuring exposure data availability before diagnosis (since July 
2005).  
4.4.3.2 The cohort and follow-up 
In total, this cohort study included 7814 women who had been diagnosed with incident colorectal 
cancer between 1 January 2006 and 31 December 2012, as ascertained from the Swedish Cancer 
Registry. Women diagnosed with colorectal cancer (ICD-10 codes C18-C20) who received at least 
one dispensed prescription of systemic MHT before their cancer diagnosis, between 1 July 2005 
and 31 December 2012, were considered prediagnostic MHT ever-users (n=1529). Women 
diagnosed with colorectal cancer not receiving menopausal hormones during the study period 
(n=6285), were classified as MHT non-users. The exposure was ascertained from the over 99% 
complete Swedish Prescribed Drug Registry. Oestrogen only, tibolone, and combination therapy 
prescriptions were classified based on ATC codes. Women were followed from cancer diagnosis 
until colorectal cancer-specific death (ICD-10 codes C18-C20, data available until 31 December 
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2013), all-cause mortality (ICD-10 codes A00-Z99, data available until 31 December 2014) or end 
of the study period (data available until 31 December 2014), as ascertained from the 100% 
complete Swedish Causes of Death Registry. Women who had undergone colorectal cancer 
surgery were identified from the Patient Registry (surgery codes are provided in Study IV, 
Supplementary Table 1). 
4.4.3.3 Statistical analyses 
We used multivariable Cox regression models to calculate hazard ratios (HRs) with 95% CIs for 
cause-specific and all-cause mortality risk among women diagnosed with colorectal cancer. All 
analyses compared MHT ever-users to MHT non-users and were adjusted for factors that might 
influence MHT prescription (id est hysterectomy, thrombotic events, and parity), age at diagnosis, 
smoking- and alcohol-related diseases, obesity, diabetes, osteoporosis (id est confounding by 
indication), site (id est colon or rectum), and stage of cancer (0+I, II, III, and IV, based on the 
Swedish guidelines). The different MHT types and the site of cancer were used to further stratify 
the analyses. Furthermore, MHT users were classified into ever, current, and past users based on 
the last dispensed prescription’s timing. Women who had received at least one dispensed 
prescription within six months before colorectal cancer diagnosis were considered current MHT 











4.5 STUDY ON ORAL ANTIBIOTIC TREATMENT 
4.5.1 Study III 
4.5.1.1 Design 
This was a systematic review and dose-response meta-analysis investigating the posed association 
between oral antibiotic treatment and the risk of colorectal cancer. Figure 4 presents an overview 
of the study design “step by step”. No additional restrictions, such as language or geographical 
area, were set for the search. Eligible studies had to provide original data comparing individuals 
who were ever exposed to antibiotics to individuals not receiving antibiotics during the study 
period, providing standardised risk estimates from a cohort or a case-control study or a randomised 
controlled trial. Cross-sectional studies, case reports, and non-peer-reviewed papers, animal- and 
in-vitro studies, as well as publications with overlapping data, were excluded. The quality 
assessment of the included publications was conducted applying New-Ottawa Scale (NOS) for 
case-control and cohort studies,(133) and we used an additional customised quality assessment 
tool based on the most important key area’s reported in each study.(134)  
 
 
Figure 4. An overview illustration of the various steps included in the study design (note: a detailed 




4.5.1.2 Statistical analyses 
A random-effects meta-analysis was conducted pooling the most adjusted standardized risk 
estimates from the original publications, generating pooled effect sized (ES) with 95% CIs for each 
of the outcomes. These analyses compared individuals exposed to antibiotics with non-users 
during the study period. The non-users were defined as having received 0-1 prescriptions during 
the study period. We undertook multiple subgroup analyses by anatomical location, study design, 
indication, and the various antibiotics classes (as reported in the original publications). 
Dose-response analyses were performed, exploring the potential dose-response relationship 
between the number of days exposed to antibiotics/number of prescriptions and colorectal cancer 
risk. Each prescription category’s median was used to quantify the exposure as a continuous 
variable. Firstly, we fitted the dose-response model within each study and applied regression 
models to estimate each study pooled study-specific trends. A Wald test was utilized to evaluate 
potential deviation from linearity, and p <0.05 was considered suggestive of departure from 
linearity.  Secondly, cubic splines were fitted, and the study-specific estimates were pooled in a 
multivariable random-effects model.(135) Statistical between studies heterogeneity was assessed 
using I2 statistics classified as <50%, 50-75%, and >75%, indicating low, moderate, and high 
heterogeneity. Egger’s test and funnel plots were employed to evaluate publication bias and small 
study effect.(136) As described in more detail in Study III, Supplementary Table 5, multiple 
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deidentified data was received from the Board in encrypted form, and the code-key to identify any 
unique individuals is held only at the Board. All data was handled with great confidentiality, 
including highly restricted permission and accessibility only from the Centre for Translational 
Microbiome Research (CTMR) at the Department of Microbiology, Tumour and Cell Biology at 
Karolinska Institutet. All data is stored within the protected domain of Karolinska Institute’s 
servers. Furthermore, no individual-level data is available for the cohort, and the results are 
presented at an aggregate level. 
We anticipate no direct risks related to those included in the study, given the included studies’ 
registry-based nature. The only potential threat to consider could be a violation of privacy; 
however, the risk of privacy violation is considered very mild given all data was received in 
anonymized and deidentified form, and all results were presented in an aggregated manner. 
Additionally, the research group has extensive experience in conducting large-scale registry-based 











In this thesis, all registry-based studies’ results were reported according to the “Strengthening The 
Reporting of Observational Studies in Epidemiology” (STROBE) statement for cohort studies.(39) 
The systematic review and dose-response meta-analysis was reported based on Preferred 
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.(137) 
5.1 STUDIES ON MENOPAUSAL HORMONE THERAPY 
5.1.1 Study I  
Most women (60%) exposed to systemic menopausal hormones were 60 years or younger at 
treatment initiation. Oestrogen-only therapy users were older at first recorded prescription 
compared to combination therapy users (Table 4). Overall, oestrogen-only therapy was less 
commonly prescribed (47.0%) than EP-MHT treatment (53.0%). The largest proportion of all 
exposed women (71.9%) received their first prescription in 2005 – 2006. 
 
Table 4. Selected characteristics of the included women who ever used menopausal hormone 




Contemporary use of menopausal hormones was associated with slightly elevated cancer risk 
(SIR=1.09, 95% CI 1.07-1.11) (Figure 5). The overall association appeared to be stronger among 
combination therapy users (SIR=1.14, 95% CI 1.12-1.17) than oestrogen-only therapy users 
(SIR=1.04, 95% CI 1.01-1.06), yet the association was inconsistent for all cancer types. As shown 
in Study I, Table 2, the here noted increased cancer risk was linked to particularly female 
reproductive organ cancers (id est breast, ovaries, and endometrium) (SIR=1.31, 95% CI 1.28-
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1.34), whilst the overall association was almost counterbalanced by the reduced risk of all cancers 
of the gastrointestinal tract (SIR=0.90, 95% CI 0.86-0.94). Among the group of gastrointestinal 
cancers, no apparent evidence was found for potential differences by choice of MHT treatment.  
 
 
Figure 5. The net effect of menopausal hormone therapy (MHT) on cancer risk, stratified by major 
cancer types and different MHT treatment options. The relative risk of cancer among MHT users, 
between 2005 and 2012, was compared to that of the female background population of the same 
age and calendar period. Abbreviations: SIR: standardized incidence ratio, 95% CI: confidence 
interval. 
 
Furthermore, the overall associations remained similar after excluding the first calendar period, 
and no apparent effect by the duration of MHT use was shown (Study I, Supplementary eTable 3). 
Of the various oestrogen formulations, a marginal association was shown for oestradiol (which 
accounted for 99% of the oestrogenic component in the combination therapy), whereas no 
association was found for oestriol (Figure 6). Per contra, tibolone use indicated for 14% increased 
cancer risk (SIR=1.14, 95% CI 1.08-1.21). Nonetheless, substantial differences were found 
particularly between the various EP-MHT treatment options, as shown in Study I, Table 3. In 
specific, continuously administered combination therapy regimes were associated with overall 
increased cancer risk. The highest risk was shown for the continuous testosterone-derived 
regimens (SIR=1.24, 95% CI 1.20-1.28), which was the most frequently prescribed EP-MHT 
regimen among the cohort (Figure 6). We found no overall association for sequentially 
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administered EP-MHT, neither progesterone-derived (SIR=1.09, 95% CI 0.91-1.29) nor 




Figure 6. The net effect of the different menopausal hormone therapy (MHT) formulations and 
regimens on cancer risk. The relative risk among women exposed to MHT between 2005 and 2012 
was compared to that of the female background population of the same calendar period and age. 
Abbreviations: SIR: standardized incidence ratio, 95% CI: 95% confidence interval. 
 
5.1.2 Study II 
This population-based matched cohort study included in total 1,155,496 women. Among them, 
288,950 women had ever received MHT, and 866,546 group-level matched controls did not 
receive menopausal hormones during the study period between 1 July 2005 and 31 December 
2012. As a result of the successful matching procedure, age and comorbidities were equally 
distributed among the groups (Table 5). 
 
During the study period, 0.2% (n=572) of ever-users of MHT were diagnosed with primary ovarian 
cancer, and respectively, 0.4% (n=3588) of women who did not receive menopausal hormones. Of 
all ovarian cancers, 95% (n=3955) accounted for cancers of epithelial origin. Among women 
exposed to MHT, the vast majority (84.0%) received orally administered MHT. Out of the various 
MHT treatment options, oestrogen-only therapy (40.7%) was prescribed to fewer women 
compared to EP-MHT (53.1%), and 6.2% of the women received tibolone. Among EP-MHT users’ 





Table 5. The main descriptive characteristics of the study cohort.  
 
 MHT ever-users MHT non-users 
 N=288,950 N=866,546 
Characteristics  Number (%) Number (%) 
All ovarian cancer  572 (0.2) 3,588 (0.4) 
Epithelial ovarian cancer  542 (0.2) 3,413 (0.4) 
Non-epithelial ovarian cancer  30 (0.0) 175 (0.0) 
Age-groups, years    
<60 years  108,134 (37.4) 324,411 (37.4) 
60-69 years  93,105 (32.2) 266,205 (30.7) 
≥70 years  87,711 (30.4) 275,930 (31.8) 
Menopausal hormone therapy   
All MHT 288,950 (100.0)  
Oestrogen only 117,506 (40.7) - 
Tibolone only 17,914 (6.2)  
Oestrogens combined progestins 153,530 (53.1) - 
Route of administration   
Oral 242,633 (84.0) - 
Cutaneous/transdermal 35,683 (12.4) - 
Oestrogen only users    
Oestradiol only 53,114 (45.2) - 
Oestriol only 55,424 (47.2) - 
Conjugated oestrogens only 1,159 (1.0) - 
Tibolone only 17,914 (6.2) - 
Oestrogen + progestin    
Progesterone derived only 47,095 (30.7) - 
Testosterone derived only 85,296 (55.6) - 
Mode of progestin administration   
Continuous only 91,982 (59.9) - 
Sequential only 28,132 (18.3) - 
Progestin regimens   
Progesterone derived, continuous 29,976 (19.5) - 
Progesterone derived, sequential 3,324 (2.2) - 
Testosterone derived, continuous 53,142 (34.6) - 
Testosterone derived, sequential 21,148 (13.8) - 
Clinical factors    
Ever parous (in-hospital delivery) 117,350 (40.6) 351,832 (40.6) 
Thrombotic events  40,165 (13.9) 120,450 (13.9) 
Hysterectomy 51,594 (17.9) 154,507 (17.8) 
Diabetes Mellitus  15,868 (5.5) 48,229 (5.6) 
Obesity 5,125 (1.8) 15,470 (1.8) 
Alcohol-related disorders  7,264 (2.5) 21,351 (2.5) 
Smoking-related disorders  13,551 (4.7) 40,826 (4.7) 
Osteoporosis  8,222 (2.9) 22,654 (2.6) 
 
Women who underwent hysterectomy with concomitant oophorectomy or salpingectomy were 
excluded from the analysis. Individuals receiving mixed therapies were excluded from the sub-







Current use of combination therapy was associated with a 38% increased ovarian cancer risk 
(OR=1.38, 95% CI 1.18-1.62), whereas we did not find an association among the past user of EP-
MHT (OR=1.00, 95% CI 0.84-1.18) or tibolone (OR=0.80, 95% CI 0.52-1.23) (Figure 7). In 
contrast, a strongly reduced ovarian cancer risk was suggested for oestrogen-only therapy users 
(OR=0.25, 95% CI 0.22-0.29%), regardless of past or current use. Furthermore, orally 
administered EP-MHT use (OR=1.23, 95% CI 1.08-1.39) suggested a more elevated cancer risk 
than cutaneous EP-MHT treatment, for which no association was found (OR=1.13, 95% CI 0.79-
1.61), based on a smaller sample. As shown in Study II, Table 3, the risk estimates for cancers of 




Figure 7. The risk of primary ovarian cancer among Swedish users of systemic menopausal 
hormone therapy (MHT) between 2005 and 2012, compared with non-users, stratified by age at 
treatment initiation, the type of MHT, and current versus past use. Abbreviations: OR: odds ratio, 






The association of different oestrogen formulations and combination therapy regimens with 
ovarian cancer risk is presented in Study II, Table 5. All the different oestrogen formulations were 
inversely associated with ovarian cancer risk, whilst we did not find an association for tibolone. 
Among EP-MHT regimens, the increased ovarian cancer risk was linked mainly to ever-use of 
continuous progestin derived regimens (OR=1.46, 95% CI 1.14-1.87) and current use of 
testosterone derived continuously administered regimens (OR=1.50, 95% CI 1.15-1.96). 
5.1.3 Study IV 
In total, this large nationwide cohort study included 7814 women diagnosed with colorectal cancer 
between 1 January 2006 and 31 December 2012, as identified from the population-level source 
cohort. Among these, 1529 women had dispensed at least one prediagnostic prescription of MHT 
prior to colorectal cancer diagnosis, and 6285 women, who were diagnosed with colorectal cancer, 
had not received MHT during the study period.  
 
Overall, most of the women (77.2%) exposed to prediagnostic MHT had received their first 
prescription during 2005. As shown in Table 6, the source cohort’s initial matching (on 1:3 ratio) 
remained rather stable, given age and comorbidities were similarly distributed among the groups. 
However, slightly larger proportion of menopausal hormone users were older than 60 years 
diagnosis (81.8%) compared to women not receiving menopausal hormones (79.6%). 
Hysterectomy was more common among women who did not receive menopausal hormones 
(30.8%) compared to prediagnostic MHT ever-users (25.7%). Notably, all the women diagnosed 
with colorectal cancer had undergone colorectal cancer surgery one year before the diagnosis and 
onwards. During the follow-up ranging from one year to eight years (median three years), a slightly 
higher proportion of women not receiving menopausal hormones died during the follow-up 
(42.0%) than hormone users (40.8%). Similarly, a somewhat lower proportion of MHT users died 
from colorectal cancer (27.3%) than MTH non-users (29.0%).  
 
The findings of this nationwide and population-level cohort study indicate that past E-MHT use is 
associated with a 33% lower colorectal cancer-specific mortality risk (HR=0.67, 95% CI 0.44-
0.99) and a 32% lower all-cause mortality risk (HR=0.68, 95% CI 0.59-0.93), compared with 
women diagnosed with colorectal cancer not receiving menopausal hormones during the study 
period (Table 7).  However, differences were observed between the menopausal hormone 
treatment types and ages. Among current users, especially E-MHT was associated with elevated 
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all-cause mortality risk (HR=1.23, 95% CI 1.02-1.48) among women 70 years or older at colorectal 
cancer diagnosis. Per contra, the use of tibolone suggested a lower mortality risk (HR=0.44, 95% 
CI 0.18-0.99). (Study IV, Table 3). Notably, current use of combination therapy among women 
aged 60-69 years was linked with an elevated risk of colorectal cancer mortality (HR=1.61, 95% 
CI 1.06-2.44) (Study IV, Table 2). Also, current MHT use among women 70 years or older 
indicated for higher colorectal cancer-specific mortality risk (HR=1.31, 95% CI 1.05-1.65); 
however, the association attenuated in subgroup-analyses by the different MHT types (Study IV, 
Table 2). Furthermore, as shown in Study IV, Supplementary Table 3, we found no apparent 



























Table 6. The main descriptive characteristics of the study included women.  
 
 MHT ever-users MHT non-users 
 Number of patients (%) Number of patients (%) 
Characteristics   
All MTH ever-users 1529 (100.0) 6285 (100.0) 
Pre-diagnostic current users* 829 (54.2)  
Pre-diagnostic past users**  700 (45.8)  
Age at diagnosis   
<60 years  279 (18.3) 1282 (20.4) 
60-69 years  529 (34.6) 1820 (29.0) 
≥70 years  721 (47.2) 3183 (50.6) 
Cancer site   
Colon 1061 (69.4) 4368 (69.5) 
Rectum 468 (30.6) 1917 (30.5) 
Site of cancer   
0+I 207 (13.4) 742 (11.9) 
II 351 (23.0) 1441 (22.9) 
III 359 (23.7) 1437 (22.8) 
IV 250 (16.3) 1126 (17.9) 
Unknown 362 (23.6) 1539 (24.5) 
Year of diagnosis   
2006-2009 829 (54.2) 3544 (56.4) 
2010-2012 700 (45.8) 2741 (43.6) 
Type of MHT therapy   
Oestrogen-only 787 (51.5)  
Tibolone only 98 (6.4)  
Oestrogens combined progestins 644 (42.1)  
Clinical factors    
Ever parous (in-hospital delivery) 373 (24.4) 1620 (25.8) 
Thrombotic events  370 (24.2) 1533 (24.4) 
Hysterectomy 393 (25.7) 1953 (30.8) 
Diabetes Mellitus  155 (10.1) 600 (9.5) 
Obesity 30 (2.0) 106 (1.7) 
Alcohol-related disorders  30 (2.0) 134 (2.1) 
Smoking-related disorders  128 (8.4) 492 (7.8) 
Osteoporosis  61 (4.0) 258 (4.1) 
 
*Women who received at least one dispensed prescription of systemic menopausal hormone 
therapy (MHT) six months prior to colorectal cancer diagnosis were considered current users. 






Table 7. The association between prediagnostic use of menopausal hormone therapy (MHT) and 
the risk of colorectal cancer-specific and all-cause mortality among the cohort included women 
diagnosed with colorectal cancer between 2006 and 2012 in Sweden. 
 
 
Multivariable adjusted HR (95% CI) * 
Colorectal cancer mortality All-cause mortality 
All MHT ever-users    
 All MHT 1.05 (0.93-1.18) 1.03 (0.93-1.14) 
Oestrogen-only 1.09 (0.92-1.29) 1.06 (0.92-1.21) 
Tibolone only 0.82 (0.53-1.28) 0.70 (0.46-1.09) 
Oestrogen + progestin 1.06 (0.89-1.25) 1.06 (0.91-1.22) 
Current users   
All MHT 1.15 (0.93-1.43) 1.16 (1.01-1.32) 
Oestrogen-only 1.15 (0.82-1.55) 1.23 (1.04-1.46) 
Tibolone only 0.57 (0.24-1.38) 0.44 (0.18-0.99) 
Oestrogen + progestin 1.25 (0.98-1.59) 1.16 (0.94-1.43) 
Past users    
All MHT  0.93 (0.79-1.09) 0.88 (0.79-0.99) 
Oestrogen-only 0.67 (0.44-0.99) 0.68 (0.59-0.93) 
Tibolone only 0.98 (0.58-1.63) 0.94 (0.56-1.56) 
Oestrogen + progestin 0.93 (0.73-1.16) 0.97 (0.80-1.18) 
Anatomical location of the tumour   
Colon 1.04 (0.90-1.19) 1.04 (0.90-1.19) 
Rectum 1.09 (0.84-1.40) 0.98 (0.79-1.21) 
*Multivariable models were adjusted for hysterectomy, thrombotic events, ever-parous, age at 
diagnosis, smoking- and alcohol-related diseases, obesity, diabetes, osteoporosis, tumour 
location, and stage of cancer. The analyses compared the mortality risk among prediagnostic MHT 
ever-users to the risk among women not exposed to menopausal hormones during the study period. 








5.2 STUDY ON ORAL ANTIBIOTIC TREATMENT  
5.2.1 Study III 
This study was a systematic review and dose-response meta-analysis. A total of 6483 non-
duplicate publications were identified, of which ten studies met the a priori defined eligibility 
criteria as shown in Figure 8. In total, this large study included over four million individuals and 
73,550 individuals with colorectal cancer. 
5.2.1.1 Included publications 
These ten included publications addressed the link between oral antibiotics and colorectal cancer 
risk compared with individuals who had not received antibiotics.(19, 123, 138-145) The studies 
were published between 1998-2020 and came from highly developed countries: The United States 
of America, Netherlands, United Kingdom, Finland, New Zealand, and Taiwan. Apart from two 
studies, the publications were case-control studies. The characteristics of the meta-analysis 
included studies are presented in Study III, Supplementary Table 3. 
All publications included only exposures to oral antibiotics. Data for cumulative antibiotic use was 
provided in six studies, whilst all apart from two studies reported antibiotic class-specific data.  
The number of antibiotic prescriptions was supplied in five publications, whilst the number of days 
exposed to antibiotics was reported in four of the publications, and only one publication utilised 
the cumulative dose expressed as tertials. Most of all included studies provided a lag-time of at 











Figure 8. A detailed Preferred Reporting Items for Systematic Reviews and Meta-analyses 









The overall risk of colorectal cancer following oral antibiotic use was 17% increased (ES=1.17, 
95% CI 1.05-1.30, N=5) among individuals who were ever exposed to antibiotics. However, the 
association attenuated in stratified analyses for colon (ES= 1.06, 95% CI 0.89-1.26, N=4) and 
rectal cancer (ES=1.01, 95% CI 0.96-1.06, N=2) separately, based on fewer studies (Figure 9).  
Furthermore, as shown in Study III, Figure 3, the association with colorectal cancer varied across 
the various classes of antibiotics. A positive association was shown for penicillin, sulphonamides, 
quinolones, cephalosporins, nitroimidazole and metronidazole with effect sizes ranging between 
1.16 to 1.33. A further subgroup meta-analysis restricted to only exposure to broad-spectrum 
antibiotics suggested a 70% (ES=1.70, 95% CI 1.26-2.30, N=3) increased risk among individuals 
ever exposed to these antibiotics, whereas we did not note any apparent link with narrow-spectrum 
antibiotics (ES=1.11, 95% CI 0.93-1.32, N=5), as shown in Study III/Supplementary Table 5.  
Figure 9. Meta-analysis of the association of oral antibiotic use with colorectal cancer risk, 
pooling together the most adjusted risk estimates from the original publications in a random-
effects model. Studies reporting antibiotic ever-use compared to non-use were included. 





The association with colorectal cancer remained positive when restricting the analyses to only 
publications adjusting for non-steroidal anti-inflammatory drug use (ES=1.06, 95% CI 1.02-1.11, 
N=2), although seemingly somewhat attenuated (Study III, Supplementary Table 5). This study 
did not reveal any firm proof for a dose-response relationship, and the risk pattern’s shape was 
similar within the colorectal continuum, as shown in Figure 10. 
 
 
Figure 10. A non-linear dose-response meta-analysis of the association between oral antibiotic 
use and risk of colorectal cancer, including studies reporting the number of days exposed to any 
antibiotics. The y-axis provides the relative risk (RR) of colorectal cancer, and the x-axis presents 
































“Science does not aim at establishing immutable truths and eternal dogmas; its aim is to 
approach the truth by successive approximations, without claiming that at any stage final and 
complete accuracy has been achieved.” 
- Bertrand Russell (1872 – 1970)
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6 METHODOLOGICAL CONSIDERATIONS 
This thesis included three nationwide and population-level cohort studies based on the Swedish 
registries and one comprehensive systematic review and dose-response meta-analysis. Each of 
these studies had different methodological challenges and different opportunities to evaluate the 
studied association. 
The methodological considerations for Study III are discussed in more detail in a separate section. 
6.1 IT’S ALL IN THE METHODS  
When one interprets the results of any scientific study, the concept of validity becomes of essential 
importance because the most important shortcomings arise from the methodological 
considerations. A poorly designed study with systematic and random errors is most likely to results 
in a wrong interpretation of the obtained results and imprecise estimates. Furthermore, there are 
also other caveats to consider, such as reverse causality, and to counteract the current 
reproducibility crisis that has shaken the scientific community; all studies should be reproducible.  
In general, an inherent limitation of observational studies is the inability to prove causality. 
However, results from a valid study based on a scientifically sound methodology might provide 
evidence to support a causal relationship. Whereas one of the main purposes of scientific studies 
is to provide evidence, causality should be carefully assessed, given the complexity of real-world 
associations. At an absolute minimum, a causal inference would require a longitudinal study that 
is completely free from all systematic and random errors, showing a biologically plausible and 
strong association without any possible alternative hypothesis that could explain the observed 
results. To add yet another layer of complexity, a dose-response relationship is an essential 
dimension of the concept of causality, assuming naturally that the shown association is biologically 
plausible to begin with. It quickly becomes relatively clear that it is not feasible to draw causal 
inference from a single study, and the same type of bias may have influenced several studies 
showing the same association. Therefore, to draw a causal inference, it could be preferable that the 
results are consistent between studies applying different designs. However, some study designs are 
more vulnerable to certain types of biases.(146, 147) 
6.2 STUDY DESIGN 
Despite the complex nature of epidemiology, epidemiologic studies are conventionally classified 
in a binary manner to either descriptive or analytical studies. Notably, both study types include 
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various study designs aiming to answer different research questions, as illustrated in Figure 11. 
Because temporality cannot be ascertained in descriptive studies, these studies are suitable to 
describe distributions of a certain event or a disease at a given point of time among a defined 
population. In contrast, analytical studies may be used to investigate the strength and direction of 
associations in particular, and these studies become useful when exploring the aetiology of a 
disease. Pharmacoepidemiological studies are often of observational design, and they are 
frequently used to describe the effect of a given drug compared with individuals who did not 
receive the drug, applying real-world registry-based data. Furthermore, common measures 
obtained from longitudinal observational studies such as incidence and mortality may be used to 
evaluate, for example, the effectiveness of preventive measures or screening programs.(146, 147)  
 
 
Figure 11. An overview of epidemiologic studies. Study designs highlighted in purple were 







Occasionally interventional studies are not accounted as epidemiological studies, possibly 
indicating that epidemiologic studies are often considered being of more observational nature. 
However, it could be argued that experimental studies such as randomised controlled trials are also 
based on rigorous epidemiological methods.  Whereas one could describe 
pharmacoepidemiological studies and trials as complementary, one of the largest differences 
between observational and experimental study designs is that it becomes overwhelmingly 
impossible to control for all the circumstances around the exposure in real-world settings. 
However, these real-world settings in a properly designed observational study may even reflect the 
clinical praxis to a greater extent compared with experimental designs.  
6.2.1 Real-world data versus clinical trials 
Whilst randomised controlled trials are often described as the golden standard, they are not suitable 
to answer all types of research questions. The benefit of pure randomisation lies in the fact that all 
potential confounding factors should be equally distributed among the study population by the 
effect of chance.(146) Given the complexity of real-world settings, identification of all potential 
confounders is challenging. In well-conducted trials, one might be more likely to control for 
confounders, which wouldn’t have been considered otherwise – again owing to the effect of pure 
chance. That being said, several trials might be severely underpowered, inherently leading to 
imprecise estimates, which might even be challenging to replicate. Besides, randomised trials also 
involve some type of selection.(2, 36, 38, 41)   
For example, MHT users are often described as somewhat healthier than women who do not 
receive MHT. This healthy user bias, and potential healthy continuer bias, may have distorted the 
found associations, particularly in observational studies.(40, 75) However, it is similarly 
questionable, who are the women participating in a randomised controlled trial? Couldn’t they, as 
well, be healthier and more educated than women who opt-out of taking part in the trial? Therefore, 
it could be argued that rigorously designed population-level studies based on real-world data may 
reflect the true population more accurately as compared with trials, enhancing the generalisability 
of the results.  
The registry-based studies included in this thesis aimed to explore the influence of menopausal 
hormones on cancer risk, and theoretically, the association could either lead to an increased or a 
decreased risk. Therefore, large clinical trials with sufficiently long follow-up time would not only 
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have been costly but, most importantly, unethical to conduct, given the potential risks could have 
over exceeded the possible health benefits.(2)  
6.2.2 Cohort studies  
The data for the thesis included registry-based studies were retrieved from the nationwide Swedish 
registries using the unique Swedish personal identity number, ensuring a valid data linkage. Given 
registration to these health data registries is mandatory,(148) the data is of high quality.  
These studies’ major strength was the population-level design reflecting real-world settings, 
inherently reducing the risk of selection bias, increasing the validity and generalisability of the 
results. Furthermore, the inclusion of virtually all Swedish women who ever received MHT 
treatment increased the statistical power to detect smaller yet meaningful associations, with 
sufficient power and follow-up time even for rare outcomes such as ovarian cancer (Study II) and 
for the different MHT treatment options. Overall, the high-quality Swedish registries have high 
coverage, completeness, and follow-up. Moreover, the risk of cancer and colorectal cancer 
mortality were evaluated longitudinally, ascertaining temporality. In contrast, many of the previous 
studies have been relatively small with power limitations, emphasizing the unmet need for valid 
and reliable large-scaled studies to clarify the role of MHT on cancer risk without exposing women 
to any potential additional risks.  
6.3 VALIDITY OF STUDY 
All risk estimates from scientific studies, no matter how rigorous the applied methods were, are, 
in fact, estimates of the true value among the studied population. A study’s validity reflects how 
valid the study and the obtained results are. In general terms, the concept of validity is subdivided 
into internal and external validity. A study with good internal validity leads to higher external 
validity, enhancing the results’ generalisability.(146)  
Internal validity is to a large extent dependent on systematic errors and various caveats in the 
methodological considerations, such as reverse causality or confounding by indication. 
Furthermore, internal validity cannot be achieved without reasonable reliability, meaning that the 
results should be reproducible in the future, and therefore this concept is closely related to 
measurement and transparency.(146)   
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6.3.1 Internal validity  
Internal validity attributes to how well a study was conducted, and this can be mainly influenced 
by systematic errors and the following shortcomings in the applied methods. Notably, these types 
of errors are not dependent on chance, and they could lead towards biased results through i) 
selection bias, ii) information bias, iii) and confounding.(146)  
 
All the studies included in this thesis applied solid methods based on a priori defined study 
protocols. The high-quality registries and the inclusion of virtually all Swedish users of systemic 
MHT (Studies I, II, and IV) enhanced the validity of the results. The data is representative to date, 
as there have been no considerable changes in clinical praxis after the study period.  
6.3.2 Selection bias  
The risk of selection bias is a general concern in observational studies and can lead to biased 
associations. Whereas the risk of systematic errors, including selection bias, cannot be entirely 
eliminated by increasing the sample size,(146) a population-based approach counteracts the extent 
of a possible selection bias, as it inherently improves the representativeness of the population. To 
additionally alleviate concerns of a potential selection bias, we took advantage of the variety of 
MHT treatment options prescribed in Sweden. We sub-grouped our analyses by the different 
treatment options (Studies I, II, and IV) and current versus past use of MHT treatment.  
However, although access to healthcare in Swedish settings should be equally distributed among 
the population, women using MHT might be healthier than women who were not prescribed MHT. 
Therefore, healthy user bias may be of concern, as a possible link between MHT use, higher 
socioeconomic status (including higher education and wealth), better health, and possibly even 
better survival has been described.(68, 149) On the other hand, women receiving MHT might 
experience more severe symptoms of menopause, warranting for treatment. Given women with 
more severe symptoms may have different levels of circulating hormones or alterations of levels 
during the menopausal transition, this could lead to a mixture of both endo- and exogenous 
hormones.(150) 
Another dimension of the healthy user bias is a healthy continuer bias. In such cases, women using 
MHT treatment could be more prone to adhere to (any) treatment compared with women not 
receiving menopausal hormones. Likewise, clinicians may be more prone to prescribe MHT to 
women who are in general healthier, and MHT is contraindicated among women who have a high 
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risk of breast cancer, women with unclear vaginal bleeding, and women with arterial or liver 
disease.(91, 151, 152)  
Altogether, these facts may contribute to the group of MHT users representing somewhat healthier 
women and limiting the generalisability of the results to healthier women without previous 
malignancy or contraindications. However, due to the successful group-level matching procedure 
in Studies II and IV, clinical factors and comorbidities were relatively equally distributed among 
MHT ever-users and MHT non-users. 
6.3.2.1 Lead-time bias and over-diagnosing bias  
Users of MHT treatment may utilize healthcare services to a greater extent as compared with MHT 
non-users. Consequently, this could lead to earlier cancer detection, selectively among users of 
menopausal hormones, potentially either over or underestimating the risk estimates.(78, 153) A 
possible over-diagnosing bias could be of concern, particularly for breast cancer, given 
mammography has been debated for the related false-positive findings.(33) This could have 
theoretically resulted in an overestimation of breast cancer in Study I. However, it would unlikely 
explain the different MHT types’ shown differences, and in the previous Nurses’ Health Study, the 
positive association with breast cancer remained significant after adjustment for mammography, 
although attenuated.(154) 
On the other hand, cancer survival depends largely on the stage of cancer but also the availability 
of screening programs and treatment.(146, 147) In Study IV, screening efforts for colorectal cancer 
could have led to earlier detection and removal of polyps, thus diminishing colorectal cancer risk 
among this group. However, there were no existing population-level screening programs for 
colorectal cancer in Sweden for the time being. Nevertheless, in Study IV, all the women diagnosed 
with colorectal cancer, from one year before the diagnosis and onwards, had undergone colorectal 
cancer surgery, which could indicate curative intent.  
6.3.3 Information bias  
Information bias might arise when exposure, outcome, or a confounding variable is misclassified. 
Depending on whether these potential errors in measurement could lead to non-differential or 
differential misclassification, they could either dilute the risk estimates towards null or result in an 




All the studies included in this thesis were based on meticulous study protocols, including detailed 
information on both the exposure and outcome. Study III was a systematic review and dose-
response analysis, yet most of the included publications were registry-based studies reducing recall 
bias risk. In the thesis included registry-based studies (Studies I, II, and IV), the exposure was 
ascertained from the highly complete (>99% for outpatient care drugs) Swedish Prescribed Drug 
Registry.(125, 155) All data on exposure was extracted in the form of ATC classification codes, 
minimising the risk of misclassification of exposure per se. To further reduce the misclassification 
of treatment type, women who received one or more oestrogen combined progestin prescriptions 
were classified as EP-MHT users. As a result, users of unopposed oestrogen-only therapy were 
strictly differentiated from women who ever received progestins, forming more homogenous 
groups. Furthermore, menopausal hormone therapy is only available on prescription in Sweden, 
and therefore over-the-counter drug use is improbable to have led to misclassification of the 
exposure. This type of misclassification could only occur when and if women bought their MHT 
treatment abroad. Still, this scenario is less likely to contribute to any significant amount of neither 
prescriptions nor MHT users.  
 
We cannot ignore the possibility of left censoring as most women (60% in Study I and II) were 
enrolled in 2005 because the Swedish Prescribed Drug Registry was first established in July 
2005.(125) This could introduce a potential misclassification of exposure and followingly age at 
treatment initiation. However, possible exposure misclassification should occur at random 
between the groups, diluting the estimates towards the null. Nonetheless, an accurate duration of 
MHT use is important, particularly if assuming causal association, as long latency-period is 
expectable for cancer-related outcomes. Therefore, to explore the potential influence of left 
censoring, we performed sensitivity analyses excluding all women with the first prescription of 
MHT in 2005 (Study I), and the results remained similar, suggesting the robustness of our results. 
Another inherent study-specific limitation for Study I is that women exposed to MHT were part of 
the background population, which could dilute the risk estimates towards the null. This may be 
particularly problematic for those cancer sites for which no apparent association was shown, and 
therefore the results should be interpreted with caution. Nonetheless, the study provided vital 
information on the net effect of menopausal hormones on cancer risk. In Studies II and IV, we 
distinguished present MHT users from incident users, stratifying the analyses by current and past 
users. Furthermore, the group-level matching aimed to reduced statistical uncertainty and to 
neutralise the effect of follow-up, enhancing the groups’ comparability.(7) 
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The Swedish Cancer Registry, which is generally over 96% complete, was used to ascertain cancer 
in Studies I, II and IV. Data is entered into the registry based on ICD-codes.(116) However, data 
for some cancer types, such as liver cancer, may be underreported in the Swedish Cancer Registry, 
owing mainly to diagnostic methods changes.(151) The Causes of Death Registry is 100% 
complete for deaths occurring in Sweden,(129) and any potential misclassification (id est cancer-
related death) should occur at random, thus potentially diluting the estimates. Whilst, in general, 
determining the cause of death might be challenging, in Study IV, all women who died from 
colorectal cancer were diagnosed with colorectal cancer at the entry of the study. This might 
alleviate concerns related to colorectal cancer-specific death’s accuracy, yet it may indicate tumour 
recurrence. Furthermore, the Swedish Patient Registry is nationwide complete since 1987 for in-
patient care records, including surgery codes.(156) Therefore, some of the hysterectomies and 
oophorectomies may have been underreported, particularly among older women. This limitation 
could explain the observed strongly reduced risk of ovarian cancer risk among women receiving 
oestrogen-only therapy in Study II. 
6.3.4 Confounding  
Confounding is a general concern for all observational studies. A confounder is a factor correlating 
with the exposure, while it is simultaneously a self-reliant risk factor for the outcome. However, it 
cannot be an intermediate factor on the pathway from exposure to the outcome. Uncontrolled or 
inadequately controlled confounding may lead to a mixture of effects and residual confounding, 
ultimately leading to a biased association and wrong interpretation of the results.(146)  
 
In the thesis included registry-based studies confounding was taken into consideration at three 
stages: i) design of the study, ii) collection of the data and iii) analysis of the data.(146) The 
population-based approach avoided selection of individuals, both exposed and non-exposed, given 
the high coverage of the Swedish Prescribed Drug Registry.(125) Whereas the inability to retrieve 
information on confounders for the entire Swedish female background population was an inherent 
limitation of the design in Study I, age is one of the major confounding factors for cancer. 
Additionally, standardisation by year of birth facilitates comparison with other studies and 
populations.(157, 158) Whereas stratification may come at the cost of external validity, 
stratification by age at treatment initiation was justified as it provided clinically valuable 
information, which can be used as an aid in clinical risk assessment. In studies II and IV, 
confounding was controlled in the study design by means of the group-level matching, and the 
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multivariable regression models were adjusted for several potential confounding variables and 
osteoporosis. 
 
Nonetheless, some registry variables might be more prone to capture the most severe cases, and 
the possibility of residual confounding cannot be ruled out. Obesity is often underreported, and the 
variables for alcohol- and smoking-related diseases may have captured individuals with heavier 
drinking and smoking habits. Moreover, data were lacking on dietary oestrogen intake, which 
could lead to an increased cumulative oestrogen intake during a lifetime. Yet, correct measurement 
of dietary factors is challenging as the standardised questionnaires also have limitations, and it is 
unclear if dietary exposure to oestrogens could be sufficient to contribute to carcinogenesis or 
mortality. Furthermore, data on previous oral contraceptive use was unavailable for our cohort. 
However, in Sweden, the users of oral contraceptives are very young concerning the studied 
outcomes, and therefore less likely to have influenced our results.(159)  
6.3.4.1 Confounding by indication 
Confounding by indication arises when the exposed individuals differ from the non-exposed 
persons by the indication of the prescribed drug.(146) Whereas alleviation of the vasomotor 
symptoms is the primary indication for MHT, menopausal hormones are also prescribed for 
osteoporosis. Therefore, we adjusted the analyses for osteoporosis in Studies II and IV. However, 
confounding by indication could be a larger issue for exposure to antibiotic treatment (Study III), 
given individuals with a high cumulative intake of oral antibiotics could have an underlying 
chronic disease warranting for the treatment. However, this might be more problematic for other 
cancer types such as lung cancer, given these individuals would be more likely to receive high 







6.4 RANDOM ERROR AND PRECISION 
Even if a study would be completely free of systematic errors, the study may not necessarily be 
free of random errors. These random errors occur due to random fluctuations in the sampling, 
causing variation in the data that cannot be explained. Random errors can be minimised by 
randomised sampling or as representative sampling as possible.  
Precision could be defined as an absence of random error, providing an estimate of the uncertainty 
of the results. It depends both on the size of the study and prevalence of the exposure, and thus a 
large sample size inherently narrows the width of the confidence intervals, providing more precise 
estimates.(146)   
To measure precision, statistical hypothesis testing providing p-values and calculation of 
confidence intervals is often applied. However, as observational studies are not randomised, the 
dichotomised statistical null-hypothesis testing may not be a preferable approach.  
6.4.1 Type I error 
Type I is a random error arising when a statistically significant association is shown, although, in 
reality, no such association exists in the study cohort. Thus, alpha error equals rejecting a true null 
hypothesis.(146) As an example, type I error could mean that we show an association between 
MHT use and cancer risk, although, in reality, no such association would exist.   
6.4.2 Statistical significance testing 
An alpha level of 0.05 provides a statistical significance level for committing an alpha error, 
meaning we accept the results occurring due to pure chance 5% of the time (160, 161). P-values 
provide information indicating the likelihood of finding the observed association or, more extreme, 
due to chance given the null hypothesis is true (id est there is no association).(146, 147) 
Occasionally, p-values are misleadingly interpreted as a simple probability. However, the p-value 
is only a threshold value for statistical significance testing, providing a cut-off level to support 
binary decision-making in terms of either keeping or rejecting the null hypothesis. Notably, p-
values do not necessarily confirm the alternative hypothesis to be true, even if the null hypothesis 
can be rejected. In return, even if the results are not significant, this can only be interpreted as an 
absence of evidence to reject the null hypothesis, which could be explained by various factors such 
as sample size. Therefore, the lack of statistical significance does not confirm that there would not 
be an effect. On the contrary, the risk with this type of binary null-hypothesis testing is that it might 
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lead to a simplistic dichotomous interpretation of the data, which is questionable given the 
complexity of real-world associations.(160, 162, 163) It could be more beneficial to assess the 
found association in terms of theories, which are not based on chance, such as systematic errors.   
6.4.3 Type II error 
Type II error arises if no statistically significant association is detected, although there is a true 
association in the study cohort.(146) This equals retaining the null hypothesis when it is false, and 
it could occur due to random noise or small sample size.  
The sample’s statistical power is the capacity to appropriately distinguish differences, thus 
rejecting the null hypothesis when it is not true. The power is conventionally set to 80%. The 
likelihood of carrying out a type II error is referred to as 𝛽-error, and the power of the sample is 
calculated by the following formula:  
Power = 1- 𝛽-error. 
The conventionally accepted level of 𝛽-error is up to 20%, meaning we accept that we don’t find 
a true association in 20% of the cases.(146)  
In this thesis included Studies I, II, and IV, the nationwide and population-based approach 
enhanced statistical power. Yet, rare cancer types had naturally smaller sample sizes, limiting the 
statistical power, particularly for subgroup analyses. Therefore, some true associations may have 
been missed due to power limitations. Study III was a systematic review and dose-response 
analysis summarising and mathematically synthesising previous knowledge, increasing the sample 
size and power. However, as for the dose-response analyses, it is expectable that the exposure is 
skewed, as fewer people are likely to receive high cumulative doses of antibiotics. Thus, the data 






6.5 CONFIDENCE  
Confidence could be defined as not finding an association when there is no association. Thus, 
confidence would be equal to stating that MHT treatment has no association with cancer risk, given 
there is no such association in the real world either.  
Confidence is calculated by the formula: 
Confidence = 1 - 𝛼 error. 
P-values provide us with information on whether the confidence interval overlaps with zero or not, 
yet they are not open or indicative of the uncertainty of results.(160) Confidence intervals, 
however, present many different aspects. In a simplistic manner, it could be stated that if one 
performs the measurement 100 times, 95% of the time, the measurement will be within the 
confidence intervals. However, confidence intervals provide not only the estimated effect but also 
the degree of uncertainty and the direction and magnitude of the association. Yet, the role of p-
values and confidence intervals is heavily dependent on the sample size, assuming an absence of 
selection bias, information bias, and confounding. Therefore, the results of a scientific study should 
be evaluated in the light of biological plausibility, previous knowledge and results, potential risk-
benefit ratios, not to forget data quality et cetera.(163) 
6.6 EXTERNAL VALIDITY  
The study’s external validity describes how well the obtained results can be generalisable to other 
populations and settings. Studies I, II, and IV included almost all Swedish users of menopausal 
hormones during the study period, facilitating the generalisability of the results to similar 
populations with comparable demographics, access to health care, related diagnostic criteria, 
applied treatment, and similar lifestyle habits.  
 
However, as we excluded all women with a history of cancer at the beginning of the study or before 
the matching procedure, our findings might not be as generalisable to women with previous cancer 
or who have received cancer treatment. Whereas not all women diagnosed with colorectal cancer 
(in entire Sweden) were included in Study IV, the study included all MHT ever-users diagnosed 





Study III included publications across various continents. However, all studies were based on 
populations from highly developed countries, limiting the generalisability of the results to 































6.7 SYSTEMATIC REVIEWS AND META-ANALYSES  
A meta-analysis is a mathematical way to quantify and produce new knowledge based on previous 
publications. As compared with other study designs, meta-analyses inherently increase the sample 
size, enhancing the statistical power, increasing the precision of the pooled effect estimates. To 
avoid biased results, a meta-analysis should always be a product of a foreseeing systematic 
literature review based on a detailed a priori established study protocol.  
The main objective of a systematic literature search is to aim to identify all relevant studies using 
several electronic databases and an additional complimentary manual search. Nonetheless, finding 
a balance between feasibility in terms of time efficiency without jeopardizing missing out on 
important publications is challenging. Theoretically, there is always a possibility that not all 
relevant papers were captured by the search. Furthermore, the a priori defined hierarchy for 
inclusion and exclusion criteria can favourably be established by applying the PICOS’ model, 
where “P” stands for population, “I” for intervention, “C” for the comparator, “O” for an outcome, 
and “S” for study design.(146) Occasionally, additional criteria are set, such as time period, 
publication language, or geographical area. However, each additional restriction may introduce 
selection and influence the generalisability of the pooled effect estimates. In Study III, no 
additional criteria were set for the search, and colleagues translated studies published in foreign 
languages.  
When the outcome is rare, standardized risk estimates can be pooled together in a meta-analysis 
providing pooled effect sizes with conventional 95% confidence intervals. Each included study is 
assigned a weight, which is influenced by sample size and confidence intervals. Thus, larger 
studies may potentially influence the results to a greater extent as compared with smaller studies, 
although the effect of weights is less prominent in random-effects models. Beyond the traditional 
meta-analytic approach, another interesting dimension for dose-response analyses is whether 
departure from linearity is present. In brief, a non-linear dose-response meta-analysis is conducted 
by i) fitting a dose-response model within each publication, ii) pooling the publication-specific 
effect estimates together, iii) testing for non-linearity using a statistical significance test, and iv) 
lastly graphing the association.(135) I would argue that in such an approach, the most challenging 
step is to find a justifiable way to quantify the exposure, as in reality, the included publications are 
likely to classify the exposure in different ways. In Study III, the exposure to antibiotics was 
quantified based on a median value of each exposure category.   
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Random-effects models assume between-study heterogeneity and take into account random error 
within each study. When the exposure is complex, it is expectable that the included publications 
do not measure the same parameter, which is one of the cornerstone assumptions of fixed-effects 
models. Therefore, random-effects models are preferable when the heterogeneity is higher, as these 
models assume in between publications heterogeneity in addition to random error.(164) 
Clinical and statistical heterogeneity might be influenced by several factors, including clinical 
settings (for example, treatment type and duration), study design, population, and follow-up time. 
Therefore, higher heterogeneity is expectable, especially if the exposure is as complex as in Study 
III. To assess statistical heterogeneity between the included publications Cochrane’s Q-test and 
Higgins’s I2 test can be applied. However, the I2 test is preferable since the Q-test has a limited 
ability to detect heterogeneity in smaller studies with low power.(164, 165) Another possibility to 
explore heterogeneity is to perform various sensitivity analyses, as was done in Study III. To 
address potential sources of heterogeneity, a meta-regression could be an option, given a 
reasonable number of publications can be included.(165)  
Furthermore, papers reporting statistically significant results might be more likely to be accepted 
for publication, possibly leading to an overestimation of the effect. Funnel plots allow us to inspect 
the presence of a potential publication bias visually, and an asymmetrical distribution could be an 
indication of this. However, the word publication bias is rather strong, and perhaps small study 
effects would be a more appropriate description of the measure.(166) To complement the visual 
assessment of funnel plots, Egger’s test estimates the potential asymmetry utilizing statistical 
significance testing. Yet, the test has limited value when less than ten publications are 
included.(136, 165) 
Several quality assessment tools may be applied simultaneously,(133, 134) and even carefully 




































































































































































































































































Nonetheless, the value of quality assessment tools should not be overestimated. Whilst these tools 
may provide valuable information to identify publications that differ from others, they are not 
entirely objective. Therefore, publications should not be excluded based on lower-quality 
assessment scoring alone. Instead, a more informative solution would be to conduct sensitivity 






















7.1 THE MAIN FINDINGS  
This thesis within clinical epidemiology has investigated the carcinogenic risks associated with 
long-term exposure to menopausal hormone therapy and oral antibiotic treatment – both 
pharmacological treatments which either include oestrogens or may modulate the metabolism of 
oestrogens. Three of the theses included publications focused on investigating the cancer risk 
among users of menopausal hormone therapy, which is the primary treatment for vasomotor 
symptoms experienced by half up to 80% of women during menopause worldwide. One of the 
publications explored the posed link between exposure to oral antibiotics and excess colorectal 
cancer risk, as the high antibiotic consumption and increasing burden of cancer underscore our 
need to consider and investigate all potential risk factors.  
We have shown that the cancer risk associated with systemic menopausal hormone therapy is 
seemingly overestimated, given the total cancer risk was only slightly increased. The excess risk 
was mainly related to female reproductive organ cancers. Per contra, MHT appeared to reduce the 
risk of gastrointestinal tract cancers, and our data indicated that prediagnostic MHT use could even 
improve survival from colorectal cancer. Overall, MHT did not appear to increase the cancer risk 
if initiated at close proximity to menopausal onset among women without contraindications or 
individuals without an increased risk of breast, ovarian or endometrial cancer. Whereas we can see 
that the number of MHT prescriptions has remained rather stable during the past decade, a deep 
drop by over 30% was noted after the millennium following the Women’s Health Trial’s results. 
This decrease in MHT prescriptions could be explained at least partly due to fear of carcinogenic 
effects. However, our results indicate that the fear of cancer risk is overestimated among otherwise 
healthy women who initiate treatment before 60 years of age.  
Furthermore, we found a link between oral antibiotic intake with an elevated colorectal cancer risk. 
This association was noted particularly among broad-spectrum antibiotic users, whilst no 
association was shown among individuals exposed to narrow-spectrum antibiotics. Moreover, the 
evidence for the non-linear dose-response relationship was weak, and the found association may 
not necessarily be of causal nature. However, together with the widespread pandemic of antibiotic 
overconsumption, these findings warrant more strict antibiotic stewardship.  
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7.2 STUDIES ON MENOPAUSAL HORMONE THERAPY 
7.2.1 Study I 
In Study I, we have shown a slightly (9%) increased total risk of cancer among contemporary users 
of systemic menopausal hormones, compared with the background population. Whereas the excess 
risk was mainly associated with typical female reproductive organ cancers, the overall risk of 
cancer was almost counterbalanced by the reduced risk of all gastrointestinal tract cancers. 
Altogether, the association appeared to be stronger among women receiving EP-MHT treatment 
than women who received oestrogen-only therapy, yet the association was inconsistent across the 
16 different cancer sites and ages. For EP-MHT users, the excess risk was associated with mainly 
continuously administered regimens. Notably, the highest excess risk was found among the most 
prescribed EP-MHT regimens, namely continuously administered testosterone-derived 
combination therapy regimen.  
 
Whilst population-level studies on the total cancer risk were relatively non-existent, our findings 
are in line with earlier studies suggesting an increased risk of particularly breast cancer, associated 
primarily with EP-MHT use (7, 10, 104, 167). Our findings support the potential role of oestrogens 
in reducing the risk of sex hormone-related cancers.(12, 15, 168, 169) In comparison to the 
Women’s Health Trial in 2002, including women 50-79 years old at the baseline (mean age 64 
years), our results showed that the risk of breast cancer changes by age at treatment initiation,(9) 
supporting the current clinical guidelines recommending treatment start before the age of 60 
years.(90, 91) Moreover, compared to our cohort, the trial participants were substantially heavier 
(≈45% of the participants who underwent hysterectomy had body mass index over 30 kg/m2), and 
thus the results could reflect a cumulative effect of endogenous and exogenous oestrogens.(9, 170) 
It has also been suggested that obese women may express more severe vasomotor symptoms, 
although underlying mechanisms are not well understood.(74) In general, as compared with a trial 
design, this present study included both prevalent and incident users of MHT. However, this 
composition reflects a real-world mixture of MHT users.  
 
In summary, contemporary use of systemic MHT treatment was linked with a slightly elevated 
total risk of cancer. However, the risk varied by women’s age at the start of the treatment and the 
various MHT treatment options. The cancer risk appeared to be minimal if treatment was initiated 
close to menopausal onset among women without contraindications or high risk of breast, ovarian 
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or endometrial cancer. Nonetheless, a thorough individual risk-benefit assessment should be 
conducted before treatment initiation, and other aspects than the potentially carcinogenic or 
chemopreventive effects should be carefully considered. 
7.2.2 Study II 
In study II we have shown that women receiving particularly current EP-MHT treatment were at 
a 38% increased risk of primary ovarian cancer compared with women not receiving menopausal 
hormones, whilst only a marginal association was noted among past EP-MHT users. In a subgroup 
analysis among EP-MHT receivers, the most prescribed continuous testosterone-derived regimens 
were linked to a 50% increased ovarian cancer risk compared with MHT non-users, whereas a 
marginal association was shown among continuous progestin-derived regimens. Notably, no clear 
association was found for sequential regimes. Among E-MHT only users, a strong inverse 
relationship with ovarian cancer was observed, yet this association requires thorough further 
clarification.  
A previous meta-analysis based on population-based studies found a 22% increased ovarian cancer 
risk among E-MHT only users.(106) One possible explanation for this discrepancy could be that 
tubal ligations and oophorectomies could be underreported in Sweden, particularly among the 
older women, as the Patient Registry became nationwide in 1987. The fact that the here found 
inverse association did not vary across different oestrogen formulations, age at initiation or current 
versus past use argues for the possibility of underreported oophorectomies. The same meta-
analysis suggested a 10% lower risk among users of EP-MHT as compared to E-MHT users,(106) 
whilst an individual participant meta-analysis including 52 studies indicated a 40% elevated 
overall risk among MHT users.(105) In this present study, EP-MHT users had a 17% increased 
risk of ovarian cancer. Whereas induction of MHT treatment is contraindicated among women 
with unknown vaginal bleeding,(91, 151, 152) the potential risk of reverse causality cannot be 
excluded. Consequently, the shown increased risk among EP-MHT users could partly be explained 
by symptoms as of yet undiagnosed ovarian cancer mistaken as menopausal symptoms, selectively 
among women with intact uterus or ovaries,(153, 171) potentially leading to overestimation of the 
risk among this group of women. 
In conclusion, especially current use of combination therapy may increase ovarian cancer risk, 
whilst the association with unopposed oestrogen-only treatment remain unclear. 
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7.2.3 Study IV 
This nationwide cohort study found over 30% lower colorectal cancer-specific and all-cause 
mortality risk among women who had received systemic menopausal hormones before their 
colorectal cancer diagnosis. The findings indicate that past use of E-MHT may improve colorectal 
cancer survival, and thus prediagnostic oestrogen-only users may have a more favourable 
prognostic outlook for colorectal cancer, compared with MHT non-users. However, current E-
MHT use was associated with elevated all-cause mortality risk, especially among women 
diagnosed at 70 years or later. Furthermore, current use of combination therapy among women 
aged 60-69 years suggested an increased risk of colorectal cancer.  
In a previous Swedish study, no association was found for post-diagnostic use of EP-MHT.(68) 
The discrepancy between our results could potentially be explained by healthy user bias. It is 
possible that particularly post-diagnostic combination therapy could be favoured among healthier 
women given the association with especially breast cancer. (7, 9, 77) Overall, our findings are 
similar to the results of a screening trial and a recent meta-analysis, both showing a reduced 
colorectal cancer-specific and all-cause mortality risk among MHT user.(70, 172) However, the 
meta-analysis, which included five cohort studies, found risk reduction among current MHT 
users.(172) Here, we observed a lower risk of colorectal cancer among past users of E-MHT. This 
discrepancy could be explained by different definitions of current versus past use. Our findings are 
biologically plausible, as it is likely that past users have been exposed to oestrogens for a longer 
duration of time, and it could be expected that the potentially protective effect of oestrogens would 
take time until it is shown. Moreover, we observed an increased risk of especially all-cause 
mortality among current E-MHT users 70 years or older. Whereas it is possible that the cell-
proliferative properties of oestrogens could contribute to this increase,(173, 174) potential reverse 
causality cannot be ruled out (id est these women may have had an underlying condition warranting 
MHT treatment). 
In conclusion, particularly past exposure to E-MHT only treatment may improve survival from 
colorectal cancer. However, the association with mortality overall varied by the different MHT 
types, age, and current versus past use. Furthermore, whereas the results of this study indicate that 
oestrogen-only therapy may have a beneficial effect, it should be considered that menopausal 
hormones are associated with other deleterious health effects such as an elevated risk of other 
cancer types and cardiovascular events.(8, 10, 85) Therefore, systemic MHT may not be a suitable 
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treatment option for all women, particularly for those at high risk for breast, ovarian or endometrial 
cancer. 
7.3 STUDY ON ORAL ANTIBIOTIC TREATMENT  
7.3.1 Study III 
This extensive systematic review and dose-response meta-analysis found a link between oral 
antibiotic treatment and colorectal cancer risk, with a modestly increased risk among individuals 
exposed to antibiotics. Notably, the excess risk of cancer was associated mainly with broad-
spectrum antibiotics, whereas narrow-spectrum antibiotics did not suggest any link. Furthermore, 
the dose-response analyses did not reveal any more substantial proof for a potential dose-response 
relationship, and risk patterns’ shapes were comparable within the colorectal continuum. However, 
the found positive association between oral antibiotic use and an increased colorectal cancer risk 
should be interpreted cautiously because this complex association may not necessarily reflect a 
causal relationship.  
7.3.1.1 Strengths and limitations  
This study’s main strength is the underlying meticulous, systematic literature review and the novel 
state-of-art methods exploring the shape of the posed risk pattern. The meta-analysis included in 
total more than four million unique individuals and over 73,550 people who had been diagnosed 
with colorectal cancer, increasing the statistical power of the study and enhancing the 
generalisability of the results. As compared with other dose-response meta-analyses, one of the 
significant advantages of this present analysis was the quantification of each exposure category 
based on the median values since a binary categorization to low versus high dose could lead to loss 
of important data.  
The main limitation of this study is the inability to draw an inference of causality, and the role of 
confounding by indication cannot be eliminated. The shown weak dose-response pattern could 
indicate confounding by indication, as indications requiring higher doses and longer duration of 
antibiotic use may indicate a chronic underlying disease rather than antibiotics causing cancer. The 
data for the dose-response relationship could be expected to be more reliable among individuals 
with lower cumulative doses, as it is likely that fewer individuals are exposed to higher doses of 
antibiotics. However, a link between antibiotic use and lung cancer has been suggested. For this 
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association, confounding by incitation could be a more significant concern, given we could expect 
higher cumulative use of antibiotic treatment for infections of the respiratory tract.(18, 175)  
Another intriguing hypothesis is the role of the gut microbiome,(120, 122, 176) underscoring the 
need for more mechanistic studies aiming to understand the drug-microbiome interactions on the 
development of colorectal cancer. The here shown differences between broad- and narrow-
spectrum antibiotics could argue for the role of antibiotic use related dysbiosis. Our findings are in 
line with a recent Swedish nested case-control study indicating a more pronounced colorectal 
cancer risk among broad-spectrum antibiotic users (OR= 1.23, 95 % CI 1.18-1.29) than narrow-
spectrum antibiotic users (OR=1.05, 95% CI 1.01-1.10).(177) Thus, the here shown association of 
oral antibiotics with increased colorectal cancer risk may not be causal, and it could indicate a 
possible role of dysbiosis in carcinogenesis. 
Nonetheless, the funnel plot was not visually symmetrical, indicating a possible presence of small-





Figure 13. The funnel of the ten included publications in Study III investigating the antibiotic use 






Furthermore, the pooled risk estimates’ comparability from the original publications might have 
been undermined by the different periods of exposure ascertainment between the included studies. 
Whereas most of the publications included in the meta-analysis had comparable exposure periods, 
beginning from the 1990s, the dose and formulations might have changed over time. Therefore, it 
should be kept in mind that the pooled effect sizes reflect a mixture of various exposures and 
periods of exposure.  
In conclusion, exposure to oral antibiotics was associated with elevated colorectal cancer risk, yet 
the shown non-linear dose-response relationship was weak, and alternative hypotheses could 





• Menopausal hormone therapy is associated only with a slightly increased total risk of 
cancer; however, the risk varies by age at treatment start and the various MHT treatment 
options.  
 
• Combination therapy is seemingly associated with increased ovarian cancer risk, whereas 
oestrogen-only therapy did not appear to increase the cancer risk. Although less frequently 
prescribed, transdermal menopausal hormones might involve a lower cancer risk than 
orally administered treatment. 
 
• Past use of oestrogen-only therapy before colorectal cancer diagnosis may improve 
survival from colorectal cancer.  
 
• Exposure to oral antibiotics is linked to increased colorectal cancer risk, yet with weak 
evidence for a non-linear dose-response relationship, and the here shown association is not 




9 POINTS OF PERSPECTIVE 
This thesis aimed to assess the long-term effects of two commonly prescribed drugs on cancer risk 
and colorectal cancer mortality. The included nationwide, population-level registry-based studies 
provided robust information that can aid in clinical risk assessment. The overall cancer risk among 
ever-users of MHT was shown to be weak, and MHT use does not appear to increase the cancer 
risk when initiated near to menopausal onset among otherwise healthy women without 
contraindications or a high risk of, especially breast, ovarian or endometrial cancer. However, the 
effect of MHT use on all-cause mortality is highly relevant when considering whether MHT 
treatment is harmful. Per contra, the association with mortality could differ from the cancer 
incidence since some evidence indicates that MHT associated tumours might have a more 
favourable prognostic outlook.  
Another interesting aspect, which has already been discussed in an international context, would be 
to investigate whether a combination of intrauterine progestin and orally or transdermally 
administered oestrogen therapy could potentially provide a safer treatment option compared with 
the currently prescribed oral EP-MHT treatment for women with an intact uterus. Here, our results 
suggested, although not confirmed, that transdermally administered systemic MHT may involve a 
lower ovarian cancer risk than oral preparations. Therefore, it would be highly informative to 
explore this potential association for other outcomes, aiming to identify safer treatment options 
with possibly lower risk of cancer and other deleterious health effects. 
Furthermore, the shown link of oral antibiotic use with an increased colorectal cancer risk perhaps 
raises more questions than the study can answer. Whereas the found association is not necessarily 
causal, the widespread pandemic of antibiotic overuse and the following subsequent problem with 
new emerging pathogens and antibiotic resistance underscores the need for more in-depth 
mechanistic studies. Considering antibiotics may not cause cancer per se, but the association could 
be mediated by the gut microbiome, this hypothesis warrants studies on potential drug-microbiome 






10 POPULÄR VETENSKAPLIG SAMMANFATTNING  
Denna doktorsavhandling syftade till att kartlägga de olika långtidseffekterna av 
hormonbehandling i klimakteriet (HT) och vanligen förskrivna antibiotika – båda utbredda 
farmakologiska behandlingar, som antingen innehåller estrogener eller kan förändra metabolismen 
av estrogener. Tre av de inkluderade publikationerna baserades på omfattande rikstäckande och 
befolkningsbaserade kohortstudier, syftandes på att utvärdera cancerrisken bland alla kvinnor som 
erhållit HT-behandling under studietiden. Hormonbehandling är den primära behandlingen för 
vasomotoriska symptom vid klimakteriet och dessa upplevs av 50 – 80 % av kvinnorna över hela 
världen. En av de inkluderade publikationerna fokuserade på antibiotikabehandlingar med 
ändamålet att undersöka det associerade sambandet mellan antibiotika med kolorektal cancerrisk. 
Detta eftersom den utbredda användningen av sedvanliga antibiotika och den ökande cancerbördan 
lyfter fram behovet att systematiskt utforska alla potentiella riskfaktorer.  
 
Denna doktorsavhandling är unik på grund av dess tre kohortstudier med riksomfattande och 
befolkningsbaserade tillvägagångsätt, baserade på de nationella svenska hög-kvalitativa 
registren. Därtill, inkluderades en stor systematisk litteratursökning och meta-analys som 
tillämpande ”state-of-art” metoder. 
 
Vi har påvisat att cancerrisken associerad med systemisk hormonbehandling till synes överskattas, 
apropå den totala nettoeffekten av HT-behandlingen på cancerutveckling var lindrig. Den förhöjda 
cancerrisken var främst associerad med bröst-, äggstocks- och livmodercancer hos kvinnor som 
inledde behandlingen i äldre ålder. Däremot fann vi indikationer för en reducerad risk av 
gastrointestinala cancrar bland HT-användare och våra data tyder på att prediagnostisk användning 
av estrogener potentiellt skulle kunna även förbättra överlevnaden från kolorektal cancer. Dessa 
resultat skulle möjligen kunna stödja den kemopreventiva rollen av estrogener associerade med 
könshormonrelaterade cancerformer.  
Medan vi har märkt att antalet utskrivna HT-recept har stannat på en relativt stabil nivå under det 
senaste decenniet, minskade antalet recept med över 30 % i Sverige efter millenium följandes 
kliniska resultat tydandes på en högre bröstcancerrisk hos kvinnor exponerade till 
hormonbehandling. Denna kraftiga nedgång i mängden av utskrivna HT-recept kan delvis 
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förklaras av rädsla för hormonbehandling associerade carcinogena effekter. Våra resultat tyder 
dock på att menopausala hormoner inte ökar cancerrisken nämnvärt om behandlingen initieras i 
nära anslutning till klimakteriets början hos annars friska kvinnor utan kontraindikationer eller en 
ökad risk för bröst-, äggstocks-, eller livmodercancer.  
Därtill upptäckte vi en koppling mellan exponering till vanligen förskrivna antibiotika och en ökad 
risk av kolorektal cancer, som var kopplad särskilt till bredspektrumantibiotika. Emellertid var 
bevis för dos-respons förhållandet svagt och den påvisade sambanden kanske inte är 
orsaksrelaterad. Icke desto mindre, tillsammans med den utbredda överanvändningen av 
antibiotika, motiverar dessa resultat ett striktare förhållningssätt till utskrivning av antibiotika.  
Avslutningsvis, denna avhandling möjliggjorde kartläggandet av cancerrisken sammankopplad till 
vanligen förskrivna läkemedel associerade med det kvinnliga könshormonet estrogen.  Våra 
resultat antyder att estrogener skulle kunna minska risken av de typiskt mansdominerande 
gastrointestinala cancrar och eventuellt även förbättra överlevnaden från könshormonrelaterade 
cancrar. De olika tillvägagångssätten som använts i de olika delstudierna försäkrade en noggrann 
utvärdering från ett flertal olika aspekter. Å andra sidan, den uppmärksammade associationen med 
vanliga antibiotika skulle kunna förklaras med alternativa hypoteser – och i synnerhet den möjliga   
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